PH26643A - Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines - Google Patents
Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines Download PDFInfo
- Publication number
- PH26643A PH26643A PH38315A PH38315A PH26643A PH 26643 A PH26643 A PH 26643A PH 38315 A PH38315 A PH 38315A PH 38315 A PH38315 A PH 38315A PH 26643 A PH26643 A PH 26643A
- Authority
- PH
- Philippines
- Prior art keywords
- parts
- methyl
- formula
- amino
- mixture
- Prior art date
Links
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 113
- -1 hydroxy, mercapto Chemical class 0.000 claims description 98
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 140
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 124
- 239000000203 mixture Substances 0.000 description 113
- 239000000543 intermediate Substances 0.000 description 112
- 239000002585 base Substances 0.000 description 109
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 81
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 62
- 239000003480 eluent Substances 0.000 description 61
- 150000003254 radicals Chemical class 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 54
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 47
- 229960001701 chloroform Drugs 0.000 description 47
- 239000000047 product Substances 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 43
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 229910021529 ammonia Inorganic materials 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 27
- 229910002027 silica gel Inorganic materials 0.000 description 27
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 25
- 238000003756 stirring Methods 0.000 description 23
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 20
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 18
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 229920002055 compound 48/80 Polymers 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000007792 addition Methods 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- 150000002825 nitriles Chemical class 0.000 description 8
- 125000003386 piperidinyl group Chemical group 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000012258 stirred mixture Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 231100000225 lethality Toxicity 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000001207 fluorophenyl group Chemical group 0.000 description 5
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(II) oxide Inorganic materials [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 230000002152 alkylating effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 3
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 3
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 3
- 239000003420 antiserotonin agent Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- QLQZBMMYHJKDSH-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]benzimidazole Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1 QLQZBMMYHJKDSH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 3H-quinazolinyl-4-one Natural products C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JCMWSVNNSPUNER-UHFFFAOYSA-N N,O-dimethyltyramine Chemical compound CNCCC1=CC=C(OC)C=C1 JCMWSVNNSPUNER-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- LVBXEMGDVWVTGY-VOTSOKGWSA-N (E)-oct-2-enal Chemical compound CCCCC\C=C\C=O LVBXEMGDVWVTGY-VOTSOKGWSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
- CBWJHIXSVFDERH-UHFFFAOYSA-N 1-isothiocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1N=C=S CBWJHIXSVFDERH-UHFFFAOYSA-N 0.000 description 1
- QYRHSCKVNACOHK-UHFFFAOYSA-N 1-methyl-2-sulfanylidenequinazolin-4-one Chemical compound C1=CC=C2C(=O)NC(=S)N(C)C2=C1 QYRHSCKVNACOHK-UHFFFAOYSA-N 0.000 description 1
- MHPLYLRFXZBLDT-UHFFFAOYSA-N 1-piperidin-4-ylbenzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1C1CCNCC1 MHPLYLRFXZBLDT-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- YAYOVHRLVOHYMW-UHFFFAOYSA-N 1h-pyrimidin-6-one;hydrochloride Chemical compound Cl.O=C1C=CN=CN1 YAYOVHRLVOHYMW-UHFFFAOYSA-N 0.000 description 1
- LNJKRDXYZRKJQD-UHFFFAOYSA-N 1h-pyrimidine-2-thione;hydrochloride Chemical compound Cl.SC1=NC=CC=N1 LNJKRDXYZRKJQD-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- ZSHDQQJQYPKAIA-UHFFFAOYSA-N 2-(6-chloropurin-9-yl)ethanol Chemical compound N1=CN=C2N(CCO)C=NC2=C1Cl ZSHDQQJQYPKAIA-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- MZTWBIOQIFRFNF-UHFFFAOYSA-N 2-amino-5-methylsulfanylbenzoic acid Chemical compound CSC1=CC=C(N)C(C(O)=O)=C1 MZTWBIOQIFRFNF-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- PQYWRHJKOWSNPL-UHFFFAOYSA-N 2-n-(pyridin-2-ylmethyl)pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1NCC1=CC=CC=N1 PQYWRHJKOWSNPL-UHFFFAOYSA-N 0.000 description 1
- HGSJSGJZOMBIAB-UHFFFAOYSA-N 2h-pyrimido[2,1-b][1,3]thiazin-6-one Chemical compound S1CC=CN2C(=O)C=CN=C21 HGSJSGJZOMBIAB-UHFFFAOYSA-N 0.000 description 1
- MTMVQZYXOQGNPS-UHFFFAOYSA-N 3-(2-hydroxyethyl)-1-methylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CCO)C(=O)N(C)C2=C1 MTMVQZYXOQGNPS-UHFFFAOYSA-N 0.000 description 1
- OMQHDIHZSDEIFH-UHFFFAOYSA-N 3-Acetyldihydro-2(3H)-furanone Chemical compound CC(=O)C1CCOC1=O OMQHDIHZSDEIFH-UHFFFAOYSA-N 0.000 description 1
- ONKFTKZSASNPJY-UHFFFAOYSA-N 3-nitro-n-(pyridin-2-ylmethyl)pyridin-2-amine Chemical compound [O-][N+](=O)C1=CC=CN=C1NCC1=CC=CC=N1 ONKFTKZSASNPJY-UHFFFAOYSA-N 0.000 description 1
- TZEVSKPZTQIPLS-UHFFFAOYSA-N 3-nitropyridine-2,6-diamine Chemical compound NC1=CC=C([N+]([O-])=O)C(N)=N1 TZEVSKPZTQIPLS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- JOTRPRKONYTVBV-UHFFFAOYSA-N 4-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CN=CC=C1Cl JOTRPRKONYTVBV-UHFFFAOYSA-N 0.000 description 1
- ZFCFBWSVQWGOJJ-UHFFFAOYSA-N 4-chlorobutanenitrile Chemical compound ClCCCC#N ZFCFBWSVQWGOJJ-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- ADOJVBUVXRZBHE-UHFFFAOYSA-N 5-(2-hydroxyethyl)-6-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC=1NC(=S)NC(=O)C=1CCO ADOJVBUVXRZBHE-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- YXMDSGMKLLNUHN-UHFFFAOYSA-N 6-(2-bromoethyl)-7-methyl-3,5-dihydro-2h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound CC1=C(CCBr)CN2CCSC2=N1 YXMDSGMKLLNUHN-UHFFFAOYSA-N 0.000 description 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 1
- GJAQIJSYKGXEBM-UHFFFAOYSA-N 6-chloro-8,9-dimethylpurine Chemical compound N1=CN=C2N(C)C(C)=NC2=C1Cl GJAQIJSYKGXEBM-UHFFFAOYSA-N 0.000 description 1
- MYZLYLSMYQVQOM-UHFFFAOYSA-N 6-methylsulfanyl-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=CC(SC)=CC=C21 MYZLYLSMYQVQOM-UHFFFAOYSA-N 0.000 description 1
- QMWPZHJFIXEZKA-UHFFFAOYSA-N 7-(2-hydroxyethyl)-8-methyl-3,4-dihydro-2h-pyrimido[2,1-b][1,3]thiazin-6-one Chemical compound S1CCCN2C(=O)C(CCO)=C(C)N=C21 QMWPZHJFIXEZKA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- 101100328896 Caenorhabditis elegans col-75 gene Proteins 0.000 description 1
- 101100459440 Caenorhabditis elegans nac-3 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 1
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 101100166793 Mus musculus Cela2a gene Proteins 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- JXVIIQLNUPXOII-UHFFFAOYSA-N Siduron Chemical compound CC1CCCCC1NC(=O)NC1=CC=CC=C1 JXVIIQLNUPXOII-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- OSHXRTVCVNSLPD-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridin-2-amine Chemical compound N1=CC=C2SC(N)=NC2=C1 OSHXRTVCVNSLPD-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 1
- 229950001684 cinanserin Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- IMLIPHSGYFXWAA-UHFFFAOYSA-N ethyl 4-(1h-benzimidazol-2-ylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1 IMLIPHSGYFXWAA-UHFFFAOYSA-N 0.000 description 1
- CXYUNWVUNJEUFI-UHFFFAOYSA-N ethyl 4-(benzylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCC1=CC=CC=C1 CXYUNWVUNJEUFI-UHFFFAOYSA-N 0.000 description 1
- WGPAAFMCWWJBMW-UHFFFAOYSA-N ethyl 4-[[2-(furan-2-ylmethylamino)pyridin-3-yl]carbamothioylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=S)NC1=CC=CN=C1NCC1=CC=CO1 WGPAAFMCWWJBMW-UHFFFAOYSA-N 0.000 description 1
- GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 1
- LKKAWMNEPUOSKW-UHFFFAOYSA-N ethyl 4-isothiocyanatopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N=C=S)CC1 LKKAWMNEPUOSKW-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- CBCYLIOZZDBHHP-UHFFFAOYSA-N hydrate trihydrobromide Chemical compound O.Br.Br.Br CBCYLIOZZDBHHP-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical class N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- ASYWICDNOQIJQJ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-nitropyridin-4-amine Chemical compound [O-][N+](=O)C1=CN=CC=C1NCC1=CC=C(F)C=C1 ASYWICDNOQIJQJ-UHFFFAOYSA-N 0.000 description 1
- LLRJMQQFKMGUBC-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-nitropyridin-3-amine Chemical compound [O-][N+](=O)C1=CC=NC=C1NCC1=CC=C(F)C=C1 LLRJMQQFKMGUBC-UHFFFAOYSA-N 0.000 description 1
- JREPCUSJHDUIBK-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-nitropyridin-3-amine;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=CC=NC=C1NCC1=CC=C(F)C=C1 JREPCUSJHDUIBK-UHFFFAOYSA-N 0.000 description 1
- QRPRTIQUWZCYNG-UHFFFAOYSA-N n-[1-(2-aminoethyl)piperidin-4-yl]-1-[(4-fluorophenyl)methyl]benzimidazol-2-amine Chemical compound C1CN(CCN)CCC1NC1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 QRPRTIQUWZCYNG-UHFFFAOYSA-N 0.000 description 1
- QRGLDPVAEILBCX-UHFFFAOYSA-N n-piperidin-4-yl-1-(pyridin-2-ylmethyl)benzimidazol-2-amine;trihydrobromide Chemical compound Br.Br.Br.C1CNCCC1NC1=NC2=CC=CC=C2N1CC1=CC=CC=N1 QRGLDPVAEILBCX-UHFFFAOYSA-N 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- NYJWYCAHJRGKMI-UHFFFAOYSA-N pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC=CN2C(=O)C=CN=C21 NYJWYCAHJRGKMI-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
Description
( . ley 93 } )
JAB 434
BICYCLIC HETEROCYCLYL CONTAINING N-(BICYCLIC HETEROCYCLYL)- 4-PIPERIDINAMINES.
En ‘ Background of the invention:
In U.S. Patent No. 4,219,559 there are described a number of
N-heterocyclyl-4-piperidinamines having the formula . r 2 r : . - I
N
1-N nf 1 3 : I | (r Ya
N— tr, : which compounds are useful as antihistaminic agents.
The compounds of the present invention differ from the prior art ) compounds essentially by the nature of the l-piperidinyl substituent and by the fact that the compounds of the present invention are not only potent histamine—antagonists but also potent serotonin- antagonists.
Ces 43 -2- i
This invention is concerned with novel N-heterocyclyl-4- piperidinamines which may structurally be represented by the formula o Bo
N 2
L-N N X er ay the pharmaceutically acceptable acid addition salts and the possible ' 10 stereochemically isomeric forms thereof, wherein: ’ : aloaZ-a3aa? igs a bivalent radical having the formula -CH=CH-CH=CH~ (a), : ~-N=CH-CH=CH~- (b), cL ~-CH=N-CH=CH~- (ce), : 15 ~CH=CH-N=CH- (a), or : © -CH=CH~CH=N- (e), wherein one or two hydrogen atoms in said radicals {a) - (e) may, each independently from each other, be replaced by halo, lower alkyl, lower alkyloxy., trifluoromethyl or hydroxy: , 20 R is a member selected from the group consisting of hydrogen and lower alkyl: rR is a member selected from the group consisting of hydrogen, alkyl, cycloalkyl, ar’ and lower alkyl substituted with one or two
Art radicals:
R> is a member selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, (lower alkyl)-CO-, lower alkyl-0-(CO)-- and
Ar’-lower alkyl: 1, is a member selected from the group consisting of a radical of formula ’ : rere tz, F (£); . (CH,) a radical of formula
Het-C_H, -Y-Alk~ (g): and a radical of formula oF Cty -3- ! aes ry tote (h), wherein n is 0 or the integer 1 or 2; s is 0 or an integer from 1 to 6 inclusive;
Alk is lower alkanediyl:
Y is 0, S, NR® or a direct bond; = :
X is 0, S, CH-NO, or nr;
Zz is 0, S, NR® or a direct bond; and
Het is an optionally substituted five- or six-membered heterocyclic } 10 ring containing at least one nitrogen atom and being condensed with an optionally substituted five- or six-membered ring, provided that: ) i) when Het is connected to C Hoe on a carbon atom then said five- or six-membered ring is not condensed with an . 15 optionally substituted benzene ring: : ii) when L is a radical either of formula (f), or of formula (g) wherein Y is other than a direct bond, or of formula } Co (h) wherein Z is other than a direct bond, wherein in said radicals (£), (g) or (h) Het is connected to CH, on a nitrogen atom then s is not 0; iii) when ateaZ-a3-n? is a radical of formula (a) or (b) and L is a radical of formula (g) wherein s is 0 and ) Y is a direct bond then Het is other than a 2,3-dihydro- ' } 2-oxo-1H-benzimidazol-1-yl or a 2,3-dihydro-3-oxo- benzoxazin-4-yl radical; said r3 being hydrogen, lower alkyl, (Ar2)lower alkyl, 2-lower alkyloxy-1,2-dioxoethyl or a radical of formula -c(=x)-r®, R® ’ being hydrogen, lower alkyl, ar, Ar2-lower alkyl, lower alkyloxy, ’
Ar2-lower alkyloxy, mono~ Or di(lower alkyl)amino, Ar2-amino,
Ar2-lower alkylamino or Ar2-lower alkyl(lower alkyl)amino: said r? being hydrogen, lower alkyl, cyano, nitro, ArZ-sulfonyl, lower alkylsulfonyl, lower alkylcarbonyl or Ar2-carbonyl: and said R® being hydrogen or lower alkyl: wherein art is a member selected from the group consisting of phenyl, being optionally substituted with up to three substituents each
Cy - oAete 3¢ -d~ independently selected from the group consisting of halo, hydroxy, nitro, cyano, trifluoromethyl, lower alkyl, lower alkyloxy, lower alkylthio, mercapto, amino, mono- and di(lower alkyl)amino, carboxyl, lower alkyloxycarbonyl and lower alkyl-CO-: thienyl; halothienyl; furanyl; lower alkyl substituted furanyl; pyridinyl: pyrazinyl; thiazolyl and imidazolyl optionally substituted by lower alkyl; and wherein Ar’ is a member selected from the group consisting of phenyl being optionally substituted with up to three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, trifluoromethyl, lower alkyl, } lower alkyloxy, lower alkylthio, mercapto, amino, mono- and di(lower alkyl)amino, carboxyl, lower alkyloxycarbonyl and {lower alkyl)-CO.
As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; the term "lower alkyl" is meant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, : 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like; "alkyl" is meant to include lower alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10 carbon atoms: the term "cycloalkyl" is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; and "lower alkanediyl" is meant to include bivalent straight or branch chained alkanediyl radicals having from 1 to 6 carbon atoms. . It is evident that in the compounds of formula (1) the bicyclic condensed ring system may be unsaturated or partly or completely saturated.
The compounds of formula (I) wherein Het is a heterocycle which is } substituted with a hydroxy, mercapto or amino radical may contain in ’ \ their structure a keto-enol tautomeric system or a vinylog system thereof and consequently these compounds may be present in their keto - form as well as their enol form.
Sct ys -5- ’
Preferred compounds within the invention are those wherein Het is a member of the group consisting of } x’ el xt Nn. & Loon x x xt
TY rH? N rH s 16
B I 13 (1~4), SY Hs (i-5), B (1-6), \__N R \_N R \ x 0 . gL’ | Re 5 & r1® N x} N- = (i=-7), LY T (i-8), and (i-9):
N= 0 wherein each x* is independently O or S: - ‘ k rR’, R®, RO, RY? and rH? are each independently hydrogen, lower alkyl, . .
Arl-lower alkyl, hydroxylower alkyl or lower alkyloxycarbonyl: ort ol
Rr’, RY, RZ, r*3, RY, rY>, r:® and r'® are each independently } . hydrogen, lower alkyl, hydroxy, mercapto, lower alkyloxy, lower . alkylthio, halo and (lower alkyloxycarbonyl)lower alkyl: . 25 p! is -CH=CH-CH=CH-, -§-CH=CH- or -N=CH-NH-: p2 is -CH=CH-CH=CH-, -S-(CHp)y, -S-(CH3)3 , orf -(CHj) 4: . 3 is -CH=CH-CH=CH-, ~CH=N-CH=CH~-, -CH_~NH-(CH,) ,=, -S~CH=CH- or -N=CH-CH=CH~-; : B? is -CH,-NH-(CHj)-, -N=CH-CH=CH- or ~N=CH-N=CH-;
Cat 30 B> is -N=CH-CH=CH-, -CH=CH-N=CH- or -CH=N-CH=N-; - B® is -CH=CH-CH=CH- or ~CH=N-CH=N~; : * . wherein one or two hydrogen atoms in said radicals sl, BZ, 82, 8,
Co B> or 8° or in the benzene part of the radicals of formula (i-2), (i-3) or (i-9) may be replaced by lower alkyl, lower alkylthio, lower
Ley -6- alkyloxy or halo where said hydrogen atom is bonded on a carbon atom, or by lower alkyl, lower alkyloxycarbonyl, Ar2-lower alkyl, where said hydrogen is bonded on a nitrogen atom.
It is clear that rR’, R®, r'2, RY, R14, rY>, R16, rt’ or Rr! is absent where the radical of formula (i-1), respectively (i-4), (i-5), (1-6) and (i-7) is connected to CH, on the atom bearing rR, RS, RZ, rL3,
R14, R15, R16, R17 or R18,
Particularly preferred compounds are those wherein L is a radical (g) or (h) wherein Het is as described hereinabove for the preferred compounds. ’ In order to simplify the structural representations of the compounds of formula (I) and of certain precursors and intermediates ’ thereof the
R rt 9 NP ~-N 0 As ~radical will hereafter be
Nap represented by the symbol D.
The compounds of formula (I) can generally be prepared by reacting an intermediate of formula (II) with a piperidine of formula (III) following art-known alkylating procedures.
Het-Q' + 0%-p alkylation (1) } reaction (11) (III)
In (II) and (I11) ot and 0° are selected so that in combination } . ‘with Het a bivalent radical of formula (f), (g) or (h) is formed during the alkylation reaction, said (££), (g) and (h) having the “ previously described meaning.
For example, the compounds of formula (I) can generally be prepared by
N-alkylating a piperidine of formula (III) wherein 0? is hydrogen, said piperidine being represented by the formula (III-a), with a reagent of formula (II) having the general formula L-W, (II-a). §
-T-
L-W + HD N-alkylation (1) (1I-a) (III-a) reaction
In (II-a) W represents an appropriate reactive leaving group such as, for example, halo, e.g., chloro, bromo or iodo, or a sulfonyloxy group, e.g. methylsulfonyloxy or_4-methylphenylsulfonyloxy.
Additionally, the compounds of formula (I) wherein L is a radical - of formula (f), a radical of formula (g) wherein Y is other than a 1 direct bond, Y , or a Yadical of formula (h) wherein Z is other than 1 a direct bond, Z°, said compounds being represented by the formulae (I-a-1), respectively (I-a~2) and (I-a-3), can be prepared by 7 alkylating an intermediate of formula (III-b) with a reagent of formula (II-b). 1 2a alkylation >
Het-C_H_ -W + Q7°-D y Het-C H_ ~ (I~a-1) s <8 reaction 5 2s (CH) 2 n (II-b) (III-b) .
X
1 1 1
Het-C H. -Y -Alk-D Het~C H_ =Z ~C-Y-Alk-D . s 2s s 2s : (I-a-2) (1-a-3)
In (III-Db) 0? is a radical of formula wf , respectively a
X (cn) 1 1 I n 1 radical of formula HY -Alk- or HZ -C-Y-Alk-. In (II-b) W has the - previously defined meaning of W and, where s is 0, it may also
A represent a lower alkyloxy, lower alkylthio or lower alkylsulfopyl group. }
The compounds of formula (I-a-2) may also be prepared by alkylating a piperidine of formula (III) wherein 0? is a radical of formula -Alk-W, said piperidine being represented by the formula (III-c), with a reagent of formula (II) wherein ot is a radical of formula ~c _H, YH, said reagent being represented by the formula (II-c).
: le v7 -8=
Het-CgHpg-Y'H + W-Alk-D alkylation = (r-a-2) —yeacEion > (I11-c) (I1I-c)
The compounds of formula (I) wherein L is a radical of formula
Het-C_H, ~2-C(=X)-¥ -ALk, said compounds being represented by the formula (I-a-4), may also be prepared by N-alkylating a piperidine of formula (III-c) with a reagent of formula (II) wherein > is a radical of formula ~c i, ~7-C(=X)-Y K, said reagent being represented by the formula (II-d).
X X
Het-C H J + (IIXI-c) alkylation Het-C H zd atk-D s 2s reaction s 2s (11-4) (I-a-4) . 15 The alkylation reactions are conveniently conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, and the like; a lower alkanol, e.g. methanol, ethanol, 1-butanol and the like; a ketone, e.9., 2-propanone, Co 4-methyl-2-pentanone and the like; an ether, e.g., 1,4-dioxane, 1,1'- oxybisethane, tetrahydrofuran and the like: N,N-dimethylformamide (DMF): N,N-dimethylacetamide (DMA); nitrobenzene; i-methyl-2-pyrroli- : dinone; and the 1ike. The addition of an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base such as, for example, N,N-diethylethanamine or §-(1-methylethyl)-2-propananine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of an iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures may enhance the rate of the reaction. ' 30 The compounds of formula (I) can also be prepared by the cyclo- desulfurization reaction of an appropriate thiourea derivative of ’ the formula 1 x
S NH 1
L-N Mand Na? .
K2 RET (IV) }
o> Lid {2 -Q-
Said cyclodesulfurization reaction may be carried out by the reaction of (IV) with an appropriate alkyl halide, preferably iodomethane in an appropriate reaction-inert organic solvent, e.g., 2 lower alkanol such as methanol, ethanol, 2-propanol and the like.
Otherwise, the cyclodesulfurization reaction may be carried out by the reaction of (IV) with an appropriate metal oxide or salt in an appropriate solvent according to art-known procedures.For example, the compounds of formula (I) can easily be prepared by the reaction of (IV) with an appropriate Hg(II) or Pb(I1) oxide or salt, such as, for example HgO, HgCl,, Hg (OAc), PbO or Pb(OAc) ,. In certain instances it may be appropriate to supplement the reaction mixture with a small amount of sulfur. Even so methanediimines, especially N,N'-methane- tetraylbis[cyclohexanamine] may be used as cyclodesulfurizing agents.
The compounds of formula (I) wherein L is a radical of formula (h) wherein Z is 2", Y is NH and X is O or §, said X being represented by x! and said compounds by the formula (I-b-1), can generally be prepared by reacting an isocyanate or isothiocyanate of formula (V) with a reagent of formula (VI). g 1 . 1 y 1 i or
Het-C H, -2 H + Xx =C=N-Alk-D —_— Het-C H, -Z -C-NH-Alk-D
So (v) (VI) (I-b-1)
Le The compounds of formula (I) wherein L is a radical of formula (h) - wherein Z is NH, Y is vt and X is xt, said compounds being . 25 represented by the formula (I-b-2), can be prepared by reacting an isocyanate or isothiocyanate of formula (VII) with a piperidine of oy formula (VIII). . x :
Het-C H. -N=c=Xx' + HYRALK-D Het-C H —wH-Boy-A1k-D “ 30 s 2s — s 2s (VII) (VIII) (1-b-2)
The reaction of (V) with (VI) and (VII) with (VIII) is generally con ducted in a suitable reaction-inert solvent such as, for example, an
L6uH|3 -10- ether, e.g. tetrahydrofuran and the like. Elevated temperatures may be suitable to enhance the rate of the reaction.
The compounds of formula (I) wherein L is a radical of formula (h) wherein Z is a direct bond and X is xt, said compounds being represented by the formula (I-c), may be prepared by reacting a piperidine of formula (VIII) with a reagent of formula (IX). x! x1
Het-C_H i + (VIII) Het-C H Ay earn (I-c) s 2s —_— s 2s (IX)
The reaction of (VIII) with (IX) may generally be conducted following art-known esterification- or amidation reaction procedures. For example, the carboxylic acid may be converted into a reactive derivative, e.g. an anhydride or a carboxylic acid halide, which subsequently, is reacted with (VIII); or by reacting (VIII) and (IX) with a suitable reagent capable of forming amides or esters, e.g. dicyclohexylcarbodiimide, 2-chloro-l-methylpyridinium iodide and the like. Said reactions are most conveniently conducted in a suitable solvent such as, for example, an ether, e.g. tetrahydrofuran, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane or a polar aprotic solvent, e.g. N,N-dimethylformamide. The addition of a base, e.g. N,N-diethylethanamine may be appropriate.
The compounds of formula (1) wherein L is a radical of formula
Co (g) wherein Y is a direct bond and s is 0, said compounds being represented by the formula (I-d), may also be prepared by reacting an appropriate alkenylene of formula (X) with a piperidine of formula ‘ 30 (III-a) by stirring and, if desired, heating the reactants together. . Het-lower alkenediyl-H + (I1XI-a) — Het-Alk-D (I-4) (X) + The compounds of formula (I) wherein L is a radical of formula (g), wherein Het is a radical of formula (i-5) wherein RY is hydrogen, . 35 g is 0, Y is a direct bond and -Alk- is -CH,-, said compounds being sete) -11-~ represented by the formula (I-e) may conveniently be prepared by reacting an intermediate of formula H-D (IIXI-a) with a reagent of formula (XI) in the presence of formaldehyde or a polymeric form thereof.
S
_N R14 N rH4
A + CHO or polymeric + (III-a) TY
B 2 — B
NN form thergof NN CH.-D 2 (X1) (I-e) : 10 Said reaction may conveniently be conducted in a suitable solvent, e.g. . . water, acetic acid, propanoic acid or mixtures of such solvents.
Elevated temperatures may be appropriate to enhance the reaction rate.
The compounds of formula (I) may also be prepared following procedures for preparing condensed bicyclic ringsystems which are known in the art or analogous procedures thereof. A number of such cyclization procedures will be described hereinafter.
The bivalent radical K used in the description of these cyclization reactions has the following meaning: -C H_ -N j=1);
Hag L > (3-1) (CH,) n : -C_H, -¥-Alk- (3-2): or
X
-C H —z-boy-nik- (3-3). s 2s .
For example, where Het is a radical of formula (i-1) being connected to K by the nitrogen atom bearing RS, said Het may be formed by ' condensing an intermediate (XII) with a Sc=x! generating agent, e.g. urea, thiourea, 1,1'~carbonylbis[1H~imidazole], lower alkyl carbono- halidate, phosgene, thiophosgene, trichloromethyl carbbnohalidate and . the like. , : 7 .
R
: 1 i —~UNH-R’ NX pl + So=xt gl | Y ~ >
C-NH~K~D NI -K-D
Hy ! generating 1 .
X agent (XII) i (I-f-1)
} . NI 73 -12-
The compounds of formula (I-f-1) wherein rR’ is hydrogen (1-f-1-a) may additionally be prepared by cyclizing an intermediate of formula x1 1 1 NH-C-NH-K-D
B 2 2 (XIII), which may in situ be generated by ‘ 10 reacting a reagent (XIV) with an amine (XV). oo N=C=X" . 2B 2 + H N-K-D (XIIX).
C-W iy
X (XV) ’ (XIV) w? as used throughout the description of the final compounds and intermediates is an appropriate reactive leaving group, such as, for example, halo, e.g., chloro, bromo or iodo, a sulfonyloxy group, e.g. ! 20 methylsulfonyloxy or 4-methylphenylsulfonyloxy, a lower alkyloxy, lower alkylthio, Ar 2-oxy or Ar’-thio group.
The reaction of (XII) with the Se=x! generating agent and the cyclization of (XIII) may conveniently be conducted in a suitable solvent such as, for example, an ether, e.g. 1,l-oxybisethane, tetrahydrofuran, an halogenated hydrocarbon, e.g. dichloromethane, trichloromethane, a hydrocarbon, e.g. benzene, methylbenzene, an alcohol, e.g. methanol, ethanol, a ketone, e.g. 2-propanone, 4-methyl-2-pentanone, N,N-dimethylformamide, N,N-dimethylacetamide, or , i mixtures of such solvents, optionally in the presence of an ; 30 appropriate base such as, for example, N,N-diethylethanamine, an . alkali or earth alkaline metal carbonate or hydrogen carbonate. In order to enhance the reaction rate, it may be suitable to heat the reaction mixture. )
~leley3 -~13-
Further, where Het is a radical of formula (i-2), said Het may be generated by cyclizing an intermediate (XVI) with an acid (XVII) or a suitable functional derivative thereof, thus giving a compound of formula (I-£-2). Alternatively an intermediate (XVIII) may be condensed with an aromatic amino acid or -thiocacid of formula (XIX), giving also a compound (1-£-2). . NH ' CI 2 + R COOH -NH-K-D 1 © (XVII) NR
X ad (XVI) N-K-D ; .
NH, 0 0 x 1 + R”-C-NH-K-D 5 c-x'H _— (1-£-2) i
X (XIX) (XVIII)
The reaction of (XVI) with (XVII) and of (XVIII) with (XIX) may be conducted in a suitable reaction-inert solvent, such as, for example, a hydrocarbon, e.g. benzene, methylbenzene, an alcohol, water. In some instances it may be appropriate to use higher temperatures in order to reduce the reaction time.
Where Het is a radical of formula (i-3), said Het may be formed by co. reacting the previously described intermediate (XVI) with an appropriate acetylene derivative (XX), thus giving a compound of . formula (I-f-3).
Fe . N H Rr (VI) + crm=c-r172 3 2 . N-K-D (XX) 1
X
(I-£-3) '
Peleg? -14-~ wherein RY %-cn - is a suitable substituent on said radical (1-3).
The reaction of (XX) with (XVI) may be conducted in a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol. Elevated temperatures may also be appropriate to shorten the reaction time.
Additionally, where Het is a radical (i-5), said Het may be created by condensing a reagent (XXI) with an intermediate (XXII), thus giving a compound (I-f-4). -
NH ’ fi N K-D 2 2 + W-CH-C-K-D : 7 Y I 15
A p13 : VN R (XXI) (XXII) (1-£-4)
Further, where Het is a radical of formula (1-6), wherein Het is connected to K by the thiazole ring, said Het may be formed during the cyclization of a reagent (XXIII) with an intermediate (XXIV); thus giving a compound (I-f-5). , Ss ’ : wo 1 s K-D
Bl + H_N-C-K-D Bt he 0 N (XXIII) (XXIV) (I-£-5)
Where Het is a radical (i-6) being connected to K by the gt containing ring and bearing a 2-mercaptosubstituent, said Het may be formed during the cyclization of an intermediate (XXV) with CS, thus giving a compound (I-£-6). : Ss. SH 4 4
B° | + cs 5 B hd ae 2 pm : K-D K-D (XXV) (I-£-6)
. llrf -15-
Where Het is a radical of formula (i-7) being connected to K either by the p> containing ring or by the imidazole ring, said Het is formed during the condensation reaction of a reagent (XXVI) with an intermediate (XXVII) respectively by the cyclodesulfurization reaction of an intermediate (XXVIII), thus giving a compound (I-£-7) respectively (I-£-8). gt? o18 I 2 . hE R2 NE
Lom (7 } HN (XXVI) (XXVIII) (1-£-7) rE’ wu-r’ ~~ 4 -D £1 cyclodesulfurization Phe to NH-G-K-D reaction : s (1-£-8) (XXVIII)
The reactions of (XXI ) with (XXII), of (XXIII) with (XXIV), 8F (XXV) So with cs, and (XXVI) with (XXVII) may conveniently conducted in a suitable reaction-inert solvent, such as for example one of the solvents given hereinabove for the preparation of (I-f-1) optionally in the presence of an appropriate base, e.g. one of the bases also described for the preparation of (I-f-1); higher temperatures may be } 55 used to enhance the reaction rate.
The cyclodesulfurization of (XXVIII) may be conducted following the same reaction circumstances as described hereinabove for the preparation of (I) starting from (IV).
Where Het is a radical (i-8), said Het may be formed furing the condensation of an intermediate (XXIX) with a Se=x* generating agent, following the same procedures as previously described for the preparation of (I-f-1) starting from (XII). rl®
NH-rY? TN k x! cL + pa s® ( FY
NH-K-D / _— N-K-D (XXIX) (1-£-8)
. or y5 -16-
The compounds of formula (I) wherein L is a radical of formula (g)., said compounds being represented by the formula (I-g), may also be generated by reducing an intermediate (XXX) with an appropriate . complex metal hydride, e.g. lithium aluminium hydride, in a suitable solvent such as, for example, an ether, e.g. tetrahydrofuran, 1,1'-oxybisethane and the like. - 0
Het-C_H, -Y-Alk' A reduction 5, Het-C_H, ~Y-Alk'-CH,-D, (XXX) (I-g)
Alk' having the previously defined meaning of Alk, provided that one methylene function is missing.
The compounds of formula (I) can also be converted into each other following art-known procedures of functional grouptrans- formation. Some examples will be cited hereinafter.
The compounds of formula (I) having a nitro substituent can be converted into their corresponding amines by stirring and, if desired, heating the starting nitro-compounds in a hydrogen- containing medium in the presence of a suitable amount of an appropriate catalyst such as, for example, platinum-on-charcoal, palladium~on-charcoal, Raney-nickel and the like catalysts. :
Suitable solvents are, for example, alcohols, e.g. methanol, ethanol and the like.
Halo atoms substituted on aryl groups may be replaced by hydrogen following art—known hydrogenolysis procedures, i.e. by stirring and, if desired, heating the starting compounds in a suitable solvent under hydrogen atmosphere in the presence of an appropriate catalyst, e.g. \ palladium-on-charcoal and the like catalysts. Said halo atoms may also be replaced by a lower alkyloxy or a lower alkylthio substituent by * reacting the starting halo-compound with an appropriate alcohol or thioalcohol or, preferably, an alkali~ or earth alkaline metal salt or ’ an appropriate alcohol or thioalcohol in a suitable solvent.
The compounds of formula (I) wherein L is a radical (g) wherein Y ’ 35 is NH can be converted into a compound of formula (I) wherein L is a i ~
. Le ley -17- radical (g) wherein Y is N-CO(lower alkyl) or N-CO(Ar?) by reacting the starting amine with an appropriate carboxylic acid or a derivative thereof such as, for example, an acid halide, an acid anhydride and the like.
The compounds of formula (I) wherein L is a radical (g) wherein Y is NH can be converted into a compound of formula (I) wherein L is a radical (g) wherein Y is N-CO(lower alkylamino), N-CO-NH-Ar>,
N-CS (lower alkylamino) or N-CS-NH-Ar> by reacting the starting amine with an appropriate isocyanate or isothiocyanate in a suitable solvent.
The compounds of formula (I) having an Het substituted with a thio ] (=) radical may be converted into the corresponding oxo (=0) analogs by reacting the former compounds with a peroxide, e.g. hydrogen peroxide, in a suitable solvent.
Compounds of formula (I) containing an Het which is unsaturated may be converted into the corresponding compounds wherein Het is saturated oo . or partly saturated following art-known reducing procedures. . . . oo In all of the foregoing and in the following preparations, the . an reaction products may be isolated from the reaction mixture and, if
Tr - 0 necessary, further purified according to methodologies genarstly «hme Ri known in the art.
The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active } non-toxic acid addition salt forms by treatment with appropriate : acids, such as, for example, inorganic acids, such as hydrohalic h 25 acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy- propanoic, ethanedioic, 2-oxopropanoic, propanedioic, butanedioic, . (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzene- sulfonic, cyclochexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxy- benzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.
Lu -18~
Some intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and others are new. A number of such preparation methods will be described hereinafter in more detail.
The intermediates of formula (III-a) can conveniently be prepared starting from a thiourea derivative of formula : R . ’ ) : Ss
Sa 10 P-N a al (XXXI) lz R52,24 . wherein P is an appropriate protective group such as, for example, lower alkyloxycarbonyl, Ar’~cH,-0-C0-, ar’-cH,- and the like, by a eyclodesulfurization reaction following the same procedure as described hereinabove for the preparation of (I) starting from (IV) and, subsequently eliminating the protective group P in the thus obtained intermediate of formula
R rl al {Hr ot Sal (XXXII) 12 | , oP
The elimination of the protective group P in (XXXII) may generally be carried out following art-known procedures such as, for example, by } 25 hydrolysis in alkaline or acidic agueous medium.
The intermediates of formula (11I-b) and (III-c) may be derived
EE from the corresponding intermediates of formula (III-a) by reacting the latter with a suitable reagent following art-known N-alkylating - procedures. .
For example, intermediates of formula (IXII-b) wherein 022 represents a radical of formula H, N-CH,-Alk'-, (III-b-1), can also be prepared by reacting an intermediate of formula (III-a) with a nitrile of formula (XXXIII) following art-known N-alkylating procedures and subsequently converting the thus obtained nitrile (XXXIV) into the corresponding amine (III-b-1) following art-known nitrile to amine : )
: ) eds -19- reducing procedures, e.g., by catalytically hydrogenating procedures and the like.
N-
NC-Alk'-W + HD alkylation yo a1xi-p reaction” (XXXIII) (III-a) (XXXIV) nitrile to amine H_N-CH,-ALk'-D (III-b-1) reduction reaction
In (XXXIII), (XXXIV) and (III-b-1) Alk' has the same meaning as Alk } provided that one methylene function is missing. i The intermediates of formula (III-b-1) may alternatively be prepared by reacting a reagent (XXXV) with (III-a) following art-known . N-alkylating procedures and subsequently converting the thus formed intermediate (XXXVI) into the free amine following art-—-known depro- tection procedures.
P-NH-Alk-W + H-D N-alkylation P-NH-Alk-D deprotection H,N-Alk-D . (XXXV) (I1I-a) (XXXVI) (1iI-b-1)
The intermediates of formula (III-b) wherein 022 represents a =! radical of formula uyl-cH_-CH,~, (III-b-2), may also be prepared So by the reaction of (III-a) with a reagent of formula (XXXV) by stirring and, if desired, heating the reactants together in a suitable ’ solvent. . 25 . E : : 1 —_ + II- HY -CH_-CH_-
CH, CH, (I1I-a) 3 CH, CH, D } } \yl” .
Y
III-b~-2 {XXXV) ( ! . 2
The intermediates of formula (III-b) wherein Q 2 is a radical of formula uyl-aix-, (III-4), may be converted into an intermediate of ' formula (III-c) by converting the function vu into an appropriate . leaving group, e.g., where v! is 0, by converting a hydroxy function into a chloro atom, with thionyl chloride, phosphoryl chloride and the like.
~ lee ys -20-
The intermediates of formula (III-b-1) may also be derived from an appropriate corresponding carbonyl-oxidated form by reacting said carbonyl-oxidated form with hydroxylamine and reducing the thus obtained oxime following art-known methods, e.g., catalytic hydrogenation and the like reducing methods.
During one of the reactions the intermediates wherein rR! and/or 3 4 “
RZ and/or R° and/or R is hydrogen may be converted into the corres- ponding intermediates wherein r! and/or Rr? and/or r3 and/or r is other than hydrogen following art-known N-alkylating, N-acylating or ' 10 reductive N-alkylating procedures. ‘ The intermediates of formula (XXXI) and the intermediates of formula (XXXI), wherein Rr? is hydrogen, said intermediates being represented : by the formula (XXXI-a), may be prepared by reacting a piperidine of formula (XXXVI-a) or (XXXVI-b) with an aromatic reagent of formula (XXXVII-a) or (XXXVII-b).
R
1
P~N NH + eT LA (XXXI-a) 2 3 24 >
R <A—A> (XXXVI-a) (XXXVII-a)
R R
: S 1 I 1 -— == Bet -———————— 0) - -— -—(C= N= em —- a Neems rE A P-N MASP (IP
AAT A-A#F (XXXVI-b) (XXXVII-b) (XXXI-a)
The intermediates of formula (XII) can conveniently be prepared by i 30 reacting an intermediate (XV) with a reagent of formula (XXXVIII) 7 “ ! N xt
B | YT + (XV) 5 (X11) .
X
1 (xxxvifr)
elegy -21-
The intermediates of formula (XV) may be prepared by N-alkylating an intermediate (III-a) with a suitable N-protected reagent, followed by an appropriate deprotection reaction.
The intermediates of formula (XIX) may be prepared by N-alkylating (III-a) with a reagent R%-CO-NH-K-W.
The intermediates of formula 4XXII) wherein W is halo, said > intermediates being represented by the formula (XXII-a), can be prepared by halogenating an intermediate {XXXIX), which can be prepared by N-alkylating (IlI-a) with a reagent of formula
R-CH,-CO-K-W. 0 halo rS-cn bxn halogenation R15 bu coxp : : {XXXIX) (XXII-a)
The intermediates of formula (XXIV) wherein K is -NH-Alk-, said intermediates being represented by the formula (XXIv-a), may be prepared by reacting an intermediate of formula (VI), wherein x* is
Ss, (Vi-a), with ammonia or an ammonium salt, e.g. ammonium chloride, in the presence of a suitable solvent such as, for example, a lower alcohol, e.g. methanol. ,
S=N=C-Alk-D ammonia or ammonium salt H N-CS-NH-Alk-D (VIi-a) (XXIV-a)
The intermediates of formula (XXV) and (XXVII) may be prepared by reacting an intermediate (III) with an appropriate reagent of formula (XL), respectively (XLI) following the same procedures as described hereinabove for the preparation of (I) starting from (II).
Ww £1 . (XL) + (III) _ > (XXV)
NH,
Q
1, (xLI) + (III) L (xXVII) ot NH, ,
. > Le 7 2, —-22-
The intermediates of formula (XXVIII) wherein K is ~NH-Alk-, said intermediates being represented by the formula (XXVIII-a), may be prepared by reacting an intermediate (VI-a) with a reagent (XLII), optionally in the presence of a suitable solvent. © ST ga
B + (VI-a) - B
NH, A (XLIX) . ’ (XXVIII-a)
The intermediates of formula (XXIX) can conveniently be prepared by :
N-alkylating an intermediate (XLIII). Said intermediate (XLIII) may be prepared by reducing an intermediate (XLIV) following art-known nitro to amine reducing procedures. es reduction LT NH, N-alkylation yuiv) : NH-K-D NH-K-D (XLIV) ‘ (XLIII)
The intermediates of formula (XLIV) may be prepared by alkylating an intermediate of formula (XV) with an appropriate N-alkylating reagent.
The intermediates of formula (XXX) can be prepared by N-acylating an intermediate (III-a) with an appropriate reagent of formula
Het-C H) -¥-ALk'-CO-i’.
The intermediates of formula (II) can conveniently be prepared ’ following art-known procedures as described in, for example, U.S.
Patent Number 4,335,127, U.S. Patent Number 4,342,870 and European
Patent Publication Number 0,070,053. ’
From formula (I) it is evident that the compounds of this invention may have several asymmetric carbon atoms in their structure. Each of these chiral centers may be present in a R~ and a S-configuration, this R- and S-notation being in correspondence with the rules described by R.S. Cahn, C. Ingold and V. Prelog in Angew. Chem., Int.
Ed. Engl., 5, 385, 511 (1966). ' Pure stereochemically isomeric forms of the compounds of formula ' (I) may be obtained by the application of art-known procedures.
. ley -23-
Diastereocisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g., counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids.
Pure stereochemically isomerig forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
It is evident that the cis and trans diastereomeric racemates may be further resolved into their optical isomers, cis(+), cis(-), trans(+) and trans(-) by the application of methodologies known to those skilled in the art.
Stereochemically isomeric forms of the compounds of formula (I) are naturally intended to be embraced within the scope of the invention.
The following examples are intended to illustrate and not to limit the scope of the present invention. Unless otherwise stated all parts therein are by weight. + . )
. oD leer 72 -24~
EXPERIMENTAL PART
A. Preparation of Intermediates
Example 1 )
A mixture of 90 parts of 4-chloro-3-nitropyridine, 71 parts of 4~fluorobenzenemethanamine, 63 parts of sodium carbonate and 900 parts of N,N-dimethylacetamide was stirred for 1 hour at 50°C. Water was added and the product was extracted with 4-methyl-2-pentanone.
The extract was dried, filtered and evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 106 parts (75%) of N-[(4-fluorophenyl)methyl]- 3-nitro-4-pyridinamine; mp. 136.8°C (intermediate 1). _ In a similar manner there were also prepared:
RY™®-cH -#N PN 2
XL 1s
R ~ A . NZ
No. RZ al=n®-a3-a4 R" mp. in °C 2 2-furanyl CH=CH-CH=CH NO, 85.6 3 4-F-C.H, CH=CH-CH=N NH, - 4 4-F-C.H, CH=N (0) ~CH=CH NO, - 255 2-pyridinyl N=CH-CH=CH NO, 113.6 6 2~-thienyl CH=CH-CH=CH NO, - 7 4-F-C.H, CH=C (OCH) ~CH=CH NO, - 8 4-F-C.H, CH=CH-C(OCH,)=CH NO, - 9 4-F-C_H, CH=CH-C(CH, )=CH NO, 99.9 ' 30|10 2-thienyl N=CH-CH=CH NO, - . 11 3-furanyl N=CH-CH=CH NO, - 12 5-methyl-2-furanyl N=CH-CH=CH NO, - ~N ele J -25-
Example 2
To a stirred and cooled (0°C) solution of 8.7 parts of N-[(4- fluorophenyl)methyl]-4-nitro-3-pyridinamine, 1-oxide and 150 parts of trichloromethane was added dropwise a solution of 10.2 parts of : 5 phosphor trichloride in 75 parts of trichloromethane. Upon completion, the mixture was allowed to reach room temperature and oo stirring was continued for one hour at reflux temperature. The reaction mixture was cooled and the solvent was evaporated. The residue was stirred in trichloromethane. The product was filtered off and dried, yielding 9 parts of N-[(4-fluorophenyl)methyl}- 4-nitro-3-pyridinamine monohydrochloride (intermediate 13).
Example 3
A mixture of 56 parts of N-(3-nitro-2-pyridinyl)-2-pyridine- methanamine, 2 parts of a solution of thiophene in ethanone 4% and 400 parts of methanol saturated with ammonia was hydrogenated at normal pressure and at room temperature with 4 parts of platinum-on- charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from acetonitrile, yielding 43.5 parts of N2-(2-pyridinylmethyl)-2,3-pyridinediamine; mp. 134.9°C (intermediate 14).
In a similar manner there were also prepared:
Re ak Kk: : : ne . 5 &
No. gl-a alaa2-p3-p4 base or mp. } salt in °C 15 2-furanyl CH=CH-CH=CH base - 16 4-F-C.H, CH=CH-N=CH base 163.7 17 4-F-CH, CH=N-CH=CH HCl 208.9 3518 2-thienyl CH=CH~CH=CH base - em mm om rm em me mm me em em ,
: Fete -26- frm Sm mm [' pI al=aZ-a3-at base or mp. ; salt in °C [9 2-furanyl N=CH-CH=CH base - 20 4-F-C_H, CH=C( OCH, )=CH=CH base - 1 4-F-CH, CH=CH-C (OCH, y=CH base - 22 4-F-CeH, CH=CH-C(CH, )=CH base - 23 2-thienyl N=CH~CH=CH base - [24 3-furanyl N=CH-CH=CH base - 25 S-methyl-2-furanyl N=CH-CH=CH base - :
Example 4
To a stirred and cooled mixture of 4 parts of sodium hydroxide in 60 parts of water were added successively 7.9 parts of carbon disulfide and 17.2 parts of ethyl 4-amino-l-piperidinecarboxylate at a temperature below 10°C. Stirring was continued for 30 minutes at this temperature. Then there were added dropwise 10.9 parts of ethyl carbonochloridate (exothermic reaction: temp. rises to about 35°C).
Upon completion, stirring was continued for 2 hours at 60°C. The i reaction mixture was cooled and the product was extracted with ’ methylbenzene. The extract was dried, filtered and evaporated, yielding 22 parts (100%) of ethyl 4-isothiocyanato-l-piperidine- carboxylate as a residue (intermediate 26).
Example 5
A mixture of 54 parts of ethyl 4-isothiocyanato~l-piperi- dinecarboxylate, 4B parts of N2-(2-furanylmethyl)-2,3-pyridine- . diamine and 450 parts of tetrahydrofuran was stirred and refluxed overnight. The reaction mixture was evaporated and the residue was ” crystallized from a mixture of 2-propanone and 2,2'-oxybispropane.
The product was filtered off and dried, yielding 76 parts (75%) of ethyl 4-[[{2-[(2-furanylmethyl)amino]-3-pyridinyl] aminothioxo- methyl]amino]-1-piperidinecarboxylate; mp. 132.7°C (intermediate 27).
Das -27-
In a similar manner there were also prepared: o RI A3,2
CH _~CH oy em 2 base 32 ull IN
Ss
No. R! al=aZ-a®=a? mp. in °C 28 2-furanylmethyl CH=CH-CH=CH - i 29 4-F~C HCH, CH=CH-CH=N - 30 4-F-C_H CH, CH=CH-N=CH 166.0 31 4-F-C HCH, CH=N-CH=CH -
Co : 15. |32 2-pyridinylmethyl N=CH-CH=CH =
IE 33 H CH=CF~CF=CH - co oo 34 2-thienylmethyl CH=CH-CH=CH -
Cee | 35 4-F-C HCH, CH=CH-C(OCH ;)=CH - . : 36 4-F-C_H CH, CH=C(OCH , }-CH=CH - {37 4~F-C HCH, CH=CH-C(CH4)=CH - 38 cyclohexyl CH=CH-CH=CH - 39 2-thienylmethyl N=CH-CH=CH - . 40 3-furanylmethyl N=CH~-CH=CH - 41 S5-methyl-2-furanyl N=CH-CH=CH - -methyl .
Example 6
A mixture of 42.5 parts of ethyl 4-[(phenylmethyl)-amino]-1- piperidinecarboxylate, 30 parts of 1-isothiocyanato-2-nitrobenzene . and 270 parts of tetrahydrofuran was stirred for 3 hours at room temperature. 2,2'-Oxybispropane was added and stirring was continued overnight. The precipitated product was filtered off and dried, yielding 48.5 parts (68.5%) of ethyl 4-([[(2-nitrophenyl)amino)-
‘ Petey -28- } amino] thioxomethyl) (phenylmethyl)amino]-1-piperidinecarboxylate; mp. 140°C (intermediate 42).
A mixture of 48.5 parts of ethyl 4-([[(2-nitrophenyl)-amino)- amino] thioxomethyl] (phenylmethyl)amino)-1-piperidinecarboxylate and 600 parts of methanol, saturated with ammonia, was hydrogenated at normal pressure and at 30°C with 45 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off over Hyflo and the filtrate was evaporated, yielding 47 parts (100%) of ethyl 4-[[ [(2-aminophenyl)- amino)amino) thioxomethyl] (phenylmethyl)amino]-1-piperidinecarboxylate - as a residue (intermediate 43). :
Example 7
A mixture of 74 parts of ethyl 4-[[[2~[(2-furanylmethyl)amino}-3- pyridinyl]aminothioxomethyl)amino]-1-piperidinecarboxylate, 96 parts of mercury({II)oxide, 0.1 parts of sulfur and 800 parts of ethanol was stirred and refluxed for 3 hours. The reaction mixture was filtered over Hyflo and the filtrate was evaporated. The residue was crystallized from acetonitrile, yielding 52.5 parts (79%) of ethyl * 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-blpyridin-2-yl]amino]-1- piperidinecarboxylate; mp. 149.2°C (intermediate 44).
In a similar manner there were also prepared: {Oy
CH=CH =0- N N Ra? base
OT
_ 25 R* ON ad
No. R Rr? al-a?-a3=nt mp. : in °C 45 2-furanylmethyl H CH=CH-CH=CE 135.8 46 4-F-C HCH, H CH=CH-CH=N 212.5 47% 4-F-C HCH, H CH=CH-N=CH - 48% 4-F-C_H CH, H CH=N-CH=CH 168.6 mmemmmosemssSomoooSssSooSTmooToTmTImImTmTITTTTTTTTT
. ME -29- o. rR} rR? al=a-a3-nt mp. in °C 49 2-thienylmethyl H CH=CH-CH=CH 142.7 50 2-pyridinylmethyl H N=CH~CH=CH 141.3 51 H H CH=CF-CF=CH 234.9 oo 52 4-F-CGH CH, H CH=CH-C(OCH,)=CH ~~ 53 4-F-C HCH, H CH=C(OCH, ) CH=CH - |54 H CeHeCH, CH=CH-CH=CH - 55 4-F-C_H CH, H CH=CH-C(CH, }=CH 202.0 56 cyclohexyl H CH=CH-CH=CH - 57 2-thienylmethyl H N=CH~CH=CH - 58 3-furanylmethyl H N=CH-CH=CH - : . 15 |59 &5-methyl-2-furanyl-H N=CH-CH=CH - methyl * . dihydrochloride monohydrate.
Example 8
A mixture of 57.5 parts of ethyl 4-(1H-benzimidazol-2-ylamino)-1- piperidinecarboxylate, 33 parts of 2-(chloromethyl)pyridine hydrochloride, 43 parts of sodium carbonate, 0.1 parts of potassium iodide and 630 parts of N,N-dimethylformamide was stirred and heated overnight at 70°C. The reaction mixture was cooled and poured onto water. The product was extracted with 4-methyl-2-pentanone. The ’ extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (96:4 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue ’ was crystallized from 4-methyl-2-pentanone, yielding 30 parts (40%) of ethyl 4-[[1-[(2-pyridinyl)methyl]}-1H-benzimidazol-2-yl)amino}-1- piperidinecarboxylate; mp. 161.5°C (intermediate 60).
Decry . ee 7° -30-
In a similar manner there were also prepared:
Loy pei
CH=CH ,~0~C-N A Ma?
TT "3 base
R= ON Xd
No. RZ ®? alaa?oa?ant mp. in °C 10 . ‘ 61 3-pyridinyl H CH=CH-CH=CH 191.4 62 2-pyrazinyl H CH=CH-CH=CH 178.5 179. 63 4-F-C.H, RH CH=CF-CF=CH 182.3 64 4-thiazolyl H CH=CH-CH=CH 156.2 65 4-F-CH, CH, CH=CH-CH=CH - 66 3-CH,=C.H, H CH=CH-CH=CH - 67 4~-F-C_H, Clg CH=CH-CH=CH - -CH,
Example 9
A mixture of 50 parts of ethyl 4~{[3-(2~furanylmethyl)-3H- imidazo[4,5-blpyridin-2-yl)amino) -1-piperidinecarboxylate, 50 parts of potassium hydroxide, 400 parts of 2-propancl and 20 drops of 2 water was stirred and refluxed for about 5 hours. The reaction mixture was evaporated and water was added to the residue. The product was extracted twice with 4-methyl-2-pentanone. The combined extracts were dried, filtered and evaporated. The solid residue was , 30 stirred in 1,1'~oxybisethane. The product was filtered off and dried, yielding 34 parts (85%) of 3-(2-furanylmethyl)-N-(4- ‘ piperidinyl)-3H-imidazo(4,5-b]pyridin-2-amine; mp. 159.0°C (intermediate 68). ;
. See 92 -3]1~
In a similar manner there were also prepared: roa
HN N Aa?
LiL .b » ase
R x4
No. R gr? al=a?-a3? mp. in °C 69 2-furanylmethyl H CH=CH-CH=CH 211.0] 70 2-thienylmethyl H CH=CH-CH=CH - } 71 4-F-C HCH, H CH=CH-C(OCH,)=~CH - * PF - ~- = 72% 4-F CH CH, CH, CH=CH-CH=CH 222.2 73 4-F-C HCH, H CH=C(OCH,)-CH=CH - . —Fe = - = - - , oF 74 4-F CH CH, H CH=CH C(CH,) CH col 75 4-F-C_H (CH, Cee CH=CH-CH=CH -
Soe et : CH, Ce Wo he A Co, 76 cyclohexyl H CH=CH-CH=CH 180.0 77 2-thienylmethyl H N=CH~-CH=CH - 78 3-furanylmethyl H N=CH-CH=CH - 79 5-methyl-2-furanyl-H N=CH-CH=CH - methyl * : dihydrochloride monohydrate.
Example 10
A mixture of 30 parts of ethyl 4-[[1-[(2-pyridinyl)methyl}-1H- ’ benzimidazol-2~yl)amino] -1-piperidinecarboxylate and 300 parts of a ‘ 30 hydrobremic acid solution 48% in water was stirred and heated for 3
CT hours at 80°C. The reaction mixture was evaporated and the residue was crystallized from methanol, yielding 41 parts {93.2%) of N-(4- piperidinyl)-1-{(2-pyridinyl)methyl]-1H-benzimidazol-2-amine tri- hydrobromide; mp. 295,9°C (intermediate BO).
: oJ lee Vg -32-
In a similar manner there were also prepared:
H ST mn X ! A ,2
NE” 7 Its 1 a0
No. p12 at=aZ-p3-at base or mp. salt form in °Q" = 81 3-pyridinyl CH=CH-CH=CH 3HBr > 260 82 2-pyrazinyl CH=CH-CH=CH 3HBr - 83 4-F-C.H, CH=CH-CH=N 2HBr + 300.6 ’ 84 4-F-CH, CH=CH~-N=CH 2HBrx 279.4 85 2-pyridinyl N=CH-CH=CH 3HBx 265.5 13 86 4-F-CH, CH=N-CH=CH 2HBr.H,0 291.6 87 4-F-CH, CH=CF~-CF=CH 2HBr 210.6 88 4-thiazolyl CH=CH-CH=CH 2HBr.H,0 223.5 89 3-CH,C An CH=CH-CH=CH 2HBr -
Example 11 50 Parts of 1-[(4-fluorophenyl)methyl)-N-(4-piperidinyl)~1H- benzimidazol-2-amine dihydrobromide were taken up in water. The free
I~ base was liberated with a sodium hydroxide solution 50% and : extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was boiled in 2-propanone. The product was filtered off and dried, yielding 17 parts (87.5%) of 1-[(4-fluoro- phenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine: mp. : : 215.5°C (intermediate 90). :
Example 12 ; A mixture of 2.1 parts of 3-buten-2-one, 9.7 parts of 1-{(4- fluorophenyl)methyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine and 120 parts of ethanol was stirred for 3 hours at reflux temperature.
The reaction mixture was evaporated. The residue was purified by
. . wey -33- column-chromatography over silica gel using a mixture of trichloro- methane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanone and 2,2'-oxybispropane, yielding 5 parts (42%) of 4-{4-[[1-[(4-fluorophenyl)methyl]-1H- benzimidazol-2-yl]amino]-l-piperidinyl]-2-butanone; mp. 131.3°C (intermediate 91).
A stirred solution of 47.5 parts of 4-[4-[(1~[(4-fluorophenyl)- : methyl] -1H-benzimidazol-2-yllamino]-1-piperidinyl])-2-butanone and 500 parts of acetic acid was acidified with a hydrobromic acid solution in glacial acetic acid. Then there were added dropwise 11.8 parts of bromine dissolved in acetic acid. Upon completion, stirring was continued overnight at room temperature. The precipitated product was filtered off and suspended in 2-propanone. The product was filtered off and dried, ylelding 23 parts (48.3%) of l-bromo- 4-[4-[[1- [(4-fluorophenyl)methyl]~1H-benzimidazol-2-yljamino}- )-piperidinyl]-2-butanone dihydrobromide (intermediate 92).
Example 13 | '
A mixture of 9 parts of oxirane, 3.24 parts of 1-(4-fluorophenyl-
E : 20 methyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine and 400 parts of methanol was stirred first overnight at room temperature and further
KE for 4 hours at 50°C. The reaction mixture was evaporated. The - residue was purified by column-chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia,
Co 25 (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a } mixture of 4-methyl-2-pentanone and 2,2'-oxybispropane, yielding 15 ’ parts of 4- [1-(4-flucrophenylmethyl)-1H-benzimidazol-2-ylamino]-1- ) " piperidineethanol; mp. 138.7°C (intermediate 93).
Example 14
A mixture of 11.5 parts of 4-chlorobutanenitrile, 48.5 parts of 1-(4-fluorophenylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine dibydrobromide, 30 parts of sodium carbonate and 270 parts of
N,N-dimethylformamide was stirred and heated overnight at 70°C. The reaction mixture was poured onto water and the product was extracted . J
. Ste 2 -34- with trichloromethane. The extract was dried, filtered and evaporated. The residue was crystallized twice from a mixture of . 4-methyl-2-pentanone and 2,2'-oxybispropane, yielding 2.2 parts (80%) of 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-y1]- amino]-1-piperidinebutanenitrile; mp. 130.5°C (intermediate 94).
In a similar manner there weré also prepared: a ) AL a’ :
NC~CH_-N N ~ base 2 OT | 12 ve
No. rt ~aten?-n3aat- np.
Cc 95 4-F-C _HZCH, ~N=CH-CH=CH~- 183.7 |96 (2-pyridinyl)methyl ~CH=CH~-CH=CH~- 152.6 97* 4-F-C_H -CH, ~CH=CH-CH=N- 173.9 98 (2-furanyl)methyl ~CH=CH-CH=CH~ 194.4 99 (2-pyridinyl)methyl ~N=CH-CH=CH- 170.0 100 (2-furanyl)methyl ~N=CH-CH=CH- 157.0 [101 (2-thienyl)methyl -CH=CH-CH=CH~ 191.7 102 C HCH, ~CH=CH-CH=CH- 180.4 103 4-F-C H,~CH, -CH=CH-C (OCH,)=CH 174.8 104 4-F-C.H,~CH, ~CH=C (OCH) -CH=CH 222.0 105 phenyl -CH=CH~CH=CH- - 106 3-CH,C.H iH, ~CH=CH-CH=CH- - * . hemihydrate .
In a similar manner there was also prepared: 4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl] amino] -1-piperidine- putanenitrile (intermediate 107).
Example 15
To a stirred mixture of 2.5 parts of lithium aluminum hydride and 225 parts of tetrahydrofuran was added dropwise a solution of 13 parts of 4-[{1-(2-thienylmethyl)~1H-benzimidazol-2-yl]lamino}-1- piperidineacetonitrile in tetrahydrofuran under nitrogen atmosphere.
. oe (ry3 ~35-
Upon completion, stirring was continued for 3 hours at reflux. The reaction mixture was cooled in an ice bath and decomposed by the } successive additions of 2.5 parts of water, 7.5 parts of a sodium hydroxide solution 15% and 7.5 parts of water. The whole was filtered over Hyflo and the filtrate was evaporated. The residue was : crystallized from acetonitrile, yielding 9.5 parts (72%) of
N-[1-(2-aminoethyl)-4-piperidinyl)-1~(2-thienylmethyl)-1H-benz- imidazol-2~amine; mp. 137.1°C (intermediate 108).
Example 16
A mixture of 12 parts of 4-[[1-{(4-fluorophenyl)methyl]-1H~ imidazo[4,5-b]pyridin-2-yl]lamino)-1-piperidineacetonitrile and 200 parts of methanol saturated with ammonia was hydrogenated at normal pressure and at room temperature with 2 parts of Raney-nickel catalyst. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from acetonitrile, yielding 10 parts (78%) of N-(1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl}-1H~ imidazol4,5-blpyridin-2-amine monohydrate; mp. 116.9°C (intermediate 109). = oo
Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared: rt 2 Nad 2 ,
H_N-(CH_) =-N NH Zz base : 2 2%n 7, TT fo co
N XV
No. n rt alea?adante TPT 110 4 4-F-C_H ~CH, -CH=CH-CH=CH- - ] Co, 111 2 4-F-CH,~CH, =N=CH~-CH=CH- 174.5 . 112 2 (2-pyridinyl)methyl -CH=CH-CH=CH- 145.1 113 2 (2-furanyl)methyl ~CH=CH-CH=CH~ 163.0 114 2 (2-pyridinyl)methyl -N=CH-CH=CH-~ 151.1 115% 2 (2-furanyl)methyl ~N=CH-CH=CH- 182.0 116 2 CeHgCH, -CH=CH-CH=CH~ 131.6 : 117 2 4-F-C_H,-CH, ~CH=CH-C(OCH,) =CH- -
or ly 7 -36- o. n r! alan? nant mp. in . °C a = 2 4-F-C HCH, ~CR=C(OCH,)-CH=CH- = ’ 119 2 CeHg -CH=CH-CH=CH~- - : 121 4 (2-furanyl)methyl -CH=CH-CH=CH- - ' * : (E)-2-butenedioate (1:3) monohydrate salt.
Example 17
A mixture of 12 parts of N-[1-(2-aminoethyl)-4-piperidinyl]- 1- [(4-£luorophenyl)methy1]-5-methoxy-1i-benzimidazol-2-anine and 150 parts of a hydrobromic acid solution 48% in water was stirred and heated for 48 hours at 80°C. The reaction mixture was evaporated and the residue was suspended in 2-propanol. The product was filtered of f and dried, yielding 18.5 parts (95.7%) of 2-{[1-(2-aminocethyl)- 4-piperidinyl]amino)-1-{(4-fluorophenyl)methyl] -1K-benzinidazol=5-ol trihydrobromide monohydrate mp. +250°C (intermediate 122).
Example 18
To a stirred and cooled (-10°C) mixture of 12.6 parts of carbon disulfide, 5.2 parts of N,N'-methanetetraylbis [cyclohexanamine] and ' .45 parts of tetrahydrofuran was added dropwise a solution of B.5 parts of N- (1-(2-aminoethy1)-4-piperidinyl] -1-(2-furanylmethyl) =H” penzimidazol-2-amine in 45 parts of tetrahydrofuran. Upon completion, gtirring was continued overnight at room temperature. The reaction mixture was evaporated and the residue was purified by column chromatography over silica gel using trichloromethane as eluent. The pure fractions were collected and the eluent was evaporated. The ' residue was crystallized from acetonitrile, yielding 6.7 parts of . 30 L- (2-furany methyl) -N- {1-(2-isothiocyanatoethyl)-4-piperidinyl}=ii- benzimidazol-2-amine (intermediate 123).
. ’ ~/ Ley 7 -37-
In a similar manner there were also prepared: rt
N lo
SCN-(CH_)_-N HH Xa base 2'm | | A3
Ss .
N Ay 1 o. m R . -alaa?oa3ands 124 2 4-F-C HCH, -CH=CH-~CH=N~- 125 2 (2-pyridinyl)methyl -N=CH-CH=CH- 126 2 4-F-C_H CH, -N=CH-CH=CH- : 127 2 (2-pyridinyl)methyl ~-CH=CH-CH=CH~- : 128 2 Celie ~CH=CH-CH=CH- 129 2 (2-thienyl)methyl ~CH=CH-CH=CH- 4-F-C_H-CH -CH=CH-CH=CH-
Ls 130 2 F Ce ic 5 CH-CH=CH 131 3. 4-F-C_H CH, ~CH=CH-CH=CH~ oo 132 2 {2-furanyl)methyl -N=CH-CH=CH-
Example 19 to 20
A mixture of 5.4 parts of 3,4-pyridinediamine, 16 parts of 1-(2~- furanylmethyl)-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl)-1H- } benzimidazol-2-amine and 135 parts of tetrahydrofuran was stirred : . and refluxed overnight. The reaction mixture was evaporated in vacuo. The residue was purified by column chromatography over silica ' ' gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent.The pure fractions were collected and the eluent was evaporated, yielding 18 parts (87%) of -
N-(4-amino-3-pyridinyl)-N'-[2-[4-[[1-(2-furanylmethyl)-1H-benzimi- dazol-2-yl)amino)~1l-piperidinyl]ethyl]thiourea (intermediate 133).
Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:
\ . or Le tej ~38~
Rr L
L y-bom (CH) A yg x 5 base
R N ry 5 134 4-amino-3-pyridinyl 2 H 4-F-C_H CH, -CH=CH-CH=CH~- - 135 3-amino-2-pyridinyl 2 H 4-F-C_H CH, -CH=CH~CH=CH- - 136 4-amino-3-pyridinyl 2 H 4-F-C_H (CH, ~CH=CH-CH=N- - 137 4-amino-3-pyridinyl 2 H 2-pyridinylmethyl -N=CH-CH=CH- - 138 d4-amino-3-pyridinyl 2 H 4-F-C_H Hy -N=CH-CH=CH- - 139 4-amino-3-pyridinyl 2 H 2-pyridinylmethyl -CH=CH-CH=CH- - 140 4-amino-3-pyridinyl 2 H Clg -CH=CH-CH=CH- - 141 4-amino-3-pyridinyl 2 H 2-thienylmethyl -CH=CH-CH=CH- - 142 5-amino-4-pyrimi- 2H 4-F-C_H CH, -CH=CH-CH=CH- - dinyl 143 4-amino-3-pyridinyl 4 H 4-F-C_H CH, -CH=CH-CH=CH- - 144 4-amino-3-pyridinyl 3 H 4-F-C HCH, -CH=CH-CH=CH- - 145 4-amino-3-pyridinyl 2 H 2-furanylmethyl -N=CH-CH=CH- -~ 146 4-(methylamino)- 2H 4-F-C HCH, -CH=CH-CH=CH- - 3-pyridinyl 147 (4-F-C_H CH,)) 2 H 4-F-C _H CH, ~CH=CH~CH=CH- - amino-3-pyridinyl 148* 4-amino-3-pyridinyl 2 CH 4-F-C_H :CH ~CH=CH-CH=CH- 128.1 3 64 2 * : monohydrate
Example 20 .
A mixture of 120 parts of methanol saturated with ammonia and 4.1 ' parts of 1-(4-f luorophenylmethyl)-N- [1-(2-isothiocyanatoethyl)=-4- piperidinyl)-1H-benzimidazol-2-amine was stirred overnight at room ’ temperature. The reaction mixture was evaporated and the residue was
. Oley ys -39- purified by column chromatography over silica gel using a mixture of trichloromethane and methanol {95:5 by volume), saturated with ammonia, as eluent. The pure fractions were collected and the eluent | : was evaporated. The residue was suspended in 1,1'-oxybisethane. The product was filtered off and crystallized from acetonitrile, yielding 1.1 parts (26%) of N-{2~{4-[{1-[(4-fluorophenyl)methyl]- 1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]thiourea; mp. 186.1°C (intermediate 149).
Example 21 :
A mixture of 3.4 parts of 6-chloro-3-nitro-2-pyridinamine, 7.4 parts of N-[1-(2-aminoethyl)-4-piperidinyl)-1-[(4-fluorophenyl)- methyl]-1H-benzimidazol-2-amine and 10 parts of l-methyl=-2- pyrrolidinone was stirred and heated for 2 hours at 150°C. The reaction mixture was cooled and taken up in methanol saturated with ammonia. The whole was evaporated and water was added to the ’ residue. The product was extracted three times with 4-methyl-2- pentanone. The combined extracts were dried, filtered and evaporated . in vacuo. The residue was purified by column chromatography over . silica gel using a mixture of trichloromethane and methanol (95:5 by zc volume) as eluent. The pure fractions were collected and the eluent . : . was evaporated. The residue was crystallized from 4-methyl-2- pentanone, yielding 5 parts (50%) of N®-[2- (4-1 [1-((4-fluoro- ! . phenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyljethyl]- . . 3-nitro-2,6-pyridinediamine; mp. 205,7°C (intermediate 150). . h
Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared: : 1-[(4-fluorophenyl)methyl}-N-[1-[2-[(2-nitrophenyl)amino]ethyl]- 4-piperidinyl]-1H-benzimidazol-2~amine; mp. 190.2°C (intermediate 151); and ‘ 6-chloro-N"-{2- [4~[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol- ’ 2-yllamino)~-1-piperidinyl}ethyl]-4,5-pyrimidinediamine; mp. 216.7°C (intermediate 152). i
’ * x da La VE -40~
Example 22 . To a stirred mixture of 9.16 parts of 2-amino-5-(methylthio)~- benzoic acid and 100 parts of 1,4-dioxane were added dropwise slowly 9.8 parts of trichloromethyl carbonochloridate. Upon completion, oo 5 stirring was continued for 2 hours. The reaction mixture was qvaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 8 parts (76%) of 6- (methylthio)-2H-3, 1-benzoxazine-2,4(1H)-dione; mp. 219.4°C (intermediate 153).
Example 23 )
A mixture of 10 parts of N-{2-(4-[[1-[(4~fluorophenyl)~ methyl] -1H-benzimidazol-2-yl}amino]-1-piperidinyljethyl]-3- nitro-2,6-pyridinediamine, 3 parts of a solution of thiophene in methanol 4% and 400 parts of methanol, saturated with ammonia, was hydrogenated at normal pressure and at room temperature with 4 parts of palladium-on~charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 9 parts (94%) of Ne-(2-[4-[[1- [(4~f luorophenyl) methyl] ~1H-benzimidazol-2-yl}amino}-1-piperidinylj~ ethyl)-2,3,6-pyridinetriamine as a residue (intermediate 154).
In a similar manner there was also prepared: :
N-[2-[4-[ [1- [(4-fLluorophenyl)methyl]~1H-benzimidazol-2-yl] amino} ~1 piperidinyllethyl]-1,2-benzenediamine (intermediate 155).
Example 24
A mixture of 4.4 parts of N-(5-bromo-1,3,4-thiadiazol-2-yl)=~ acetamide, 7.3 parts of N-[1-(2-aminoethyl)~-4-piperidinyl]-1-{(4~ fluorophenyl)methyl}-1H-benzimidazol-2-amine, 3.18 parts of sodium carbonate and 135 parts of N,N-dimethylformamide was stirred overnight at 80-90°C. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of acetonitrile and 2,2'-oxybispropane, yielding 1.7 parts of
N-(2- [4-[ [1- [(4-fluorophenyl) methyl] -1H-benzimidazol-2-yl]amino}-1= !
AD ere 7 -41- piperidinyllethyl] formamide; mp. 153.2°C (intermediate 156).
Example 25 .
To a stirred and hot (50°C) mixture of 4.1 parts of 2H-3,1- benzoxazine-2,4(1H)-dione and 31.5 parts of N,N-dimethylformamide was added dropwise a solution of 9.4 parts of N-(1-(2-aminoethyl)-4- piperidinyl]-1-[(4-fluorophenylimethyl]-1H-benzimidazol-2-amine in 31.5 parts of N,N-dimethylformamide at 50°C. Upon completion, stirring was continued for 3 hours at 50°C. Water was added and the product was extracted with 4-methyl-2-pentanone. The extract was dried, filtered and evaporated. The residue was crystallized from acetonitrile, yielding 9.8 parts (B0%) of 2-amino-N-[2-(4-[[1-[(4- } f1uorophenyl)-methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]- ethyl}benzamide; mp. 171.7°C (intermediate 157).
In a similar manner there were also prepared: 2- (ethylamino)-N={2-[4-[[1-{4-(fluorophenyl)methyl]-1H-benzimidazol=~ 2-yl)amino)-1-piperidinyl]ethyl]benzenamide; mp. 139.8°C (intermediate 158); Co
Co i= [2- [4- [ [1- [ (4-£luorophenyl)methyl] ~1H-benzimidazol-2-y1]anino]- )
BE . 1-piperidinyllethyl}-2-(methylamino)benzamide monohydrate; . 5p Mp. 147.8°C (intermediate 159); 2-amino-N-[2- [4 [ [1-(2-furanylmethy1)~1H-benzinidazol-2-y1}amino] -1- piperidinyllethyl]benzamide; mp. 167.3°C (intermediate 160); ‘ , N-[2- [4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yllamino]-1-piperi- ’ dinyl)ethyl]-2-(methylamino)benzamide monohydrate; mp. 133,0°C (intermediate 161); 2-amino-N- [4- [4-[ [1-(2-furanylmethyl)-1H-benzimidazol-2-yl}amino}=1- } piperidinyl]butyl])benzamide; mp. 151.0°C (intermediate 162); . 2-amino-N- {4- [4-1 [1-[(4-f1luorophenyl)methyl) -1H-benzimidazol-2-yl]- amino] -1-piperidinyl)butyllbenzamide: mp. 186.7°C (intermediate 163): and 2-amino-N-[2- [4-[ [1-[(4-fluorophenyl) methyl] -1H-benzimidazol-2-yl]~ amino] -1-piperidinyllethyl}-5-(methylthio)benzamide: mp. 184.6°C (intermediate 164). . H. y ' i
: : Seed 3 i -42-
Example 26
A mixture of 1.5 parts of 6-chloro-N'-[2-[4-[[1-[(4-fluoro- ; phenyl ymethyl]- 1i-benzinidazol-2-yl] amino) -1-piperiainyllethyl)=- 4,5-pyrimidinediamine, 3 parts of a solution of thiophene in ethanol 4%, 1 part of potassium acetate and 120 parts of methanol was hydrogenated at normal pressure and at room temperature with 1 part of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the . filtrate was evaporated. The solid residue was taken up in water.
The solution was treated with ammonia. The product was extracted with trichloromethane. The organic layer was separated, dried, filtered and evaporated. The residue vas crystallized from a mixture of 4-methyl-2-pentanone, yielding 1 part (72.4%) of Ni [2-14- [ (1-[(4-fluorophenyl)methyl]~-1H-benzimidazol-2-yl]amino]-1~ piperidinyllethyl]-4,5-pyrimidinediamine; mp. 207.7°C (intermediate 165).
Example 27
A mixture of 30 parts of 4-hydroxy-2-mercapto-6-methyl-5- pyrimidineethanol, 25 parts of potassium carbonate, 270 parts of
N,N-dimethylacetamide and 75 parts of water was stirred at room temperature and 36 parts of 1,3-dibromopropane were added at once: temperature rises to 50°C. The whole was stirred overnight at room temperature. The reaction mixture was evaporated and water was added to the residue. The solid product was washed with water and dried in vacuo at 100°C, yielding 21 parts (58%) of 3, 4~dihydro-7-(2-hydroxy- ethyl)-8-methyl-2H, 6H-pyrimido[2,1-b] [1,3] thiazin-6-one; mp. 155°C (intermediate 166). ‘ . , In a similar manner there was also prepared: 2, 3-aihydro-6-(2-hydroxyethyl)-7-methyl-5H-thiazolo(3, 2-a]pyrimidin= . 30 5-one; mp. 148.7°C (intermediate 167).
Example 28
A mixture of 20 parts of 3, 4-dihydro-7-(2-hydroxyethyl)-8-methyl- 2H, 6H-pyrimido(2,1-b] (1,3]thiazin-6-one, 50 parts of acetic acid and 180 parts of a hydrobromic acid solution 67% in acetic acid was gtirred and heated to reflux. Stirring was continued overnight at to ’ yy -43~ reflux temperature. The reaction mixture was evaporated and the solid residue was triturated in 2-propanone. The product was filtered off and dried, yielding 24 parts (100%) of 7-(2~bromo- ethyl)-3,4-dihydro-8-methyl-2H, 6H-pyrimido(2,1-b] [1,3]thiazin-6-one monohydrobromide; mp. 215°C (intermediate 168).
In a similar manner there was also prepared: 6-(2-bromoethyl)-2,3-dihydro-7-methyl-5H-thiazolo(3,2-a)pyrimidin=
S-one monohydrobromide; mp. 237.2°C (intermediate 169).
Example 29
A mixture of 27 parts of ethyl 2-[(ethoxycarbonyl)methylamino]~- benzoate, 16 parts of 2-aminoethanol and 90 parts of dimethylbenzene was stirred and refluxed overnight. The reaction mixture was cooled. .
The precipitated product was filtered off and crystallized from 2-propancl, yielding 4.5 parts (20%) of 3-(2-hydroxyethyl)~l-methyl- 2,4(1H, 34) -quinazolinedione (intermediate 170). ‘
A mixture of 4.5 parts of 3-(2-hydroxyethyl)-1-methyl-2,4(1H, 3H) quinazolinedione, B parts of thionyl chloride and 75 parts of ° - : trichloromethane was stirred and refluxed for 5 hours. The reaction i; . mixture was evaporated, yielding 4.5 parts (95%) of 3-(2-chloro- tb ethyl)-l-methyl-2,4 (1H, 3H)-quinazolinedione as a residue . (intermediate 171). CL ) }
Example 30 :
A mixture of 50 parts of 2-thiazolamine, 76 parts of 3-acetyl- 4,5-dihydro-2(3H)-furanone, 1.2 parts of concentrated hydrochloric acid and 270 parts of methylbenzene was stirred and refluxed for 2 hours using a water-separator. The reaction mixture is cooled and 340 parts of phosphoryl chloride were added at a temperature between , 20 and 30°C. The whole was heated slowly to 100-110°C and stirring ) was continued for 2 hours at this temperature. The reaction mixture . 30 was evaporated and the residue was poured onto a mixture of crushed , jce and ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. , The residue was purified by column chromatography over silica gel . using a mixture of trichloromethane and methanol (95:5 by volume) as ry 35 eluent. The pure fractions were collected and the eluent was . ! b ‘
: 7 Cet v3 —44- evaporated. The residue was crystallized from a mixture of 2-propanocl and 1,1'-oxybisethane, yielding 36 parts of 6-(2-chloro- ethyl)-7-methyl-SH-thiazolo(3,2-alpyrimidin-5-one (intermediate 172).
Example 31
A mixture of 4.76 parts of g-chloro-N-methyl-4,5-pyridine- diamine, 26.6 parts of 1,1,l-triethoxyethane and 30 parts of acetic acid anhydride was stirred and refluxed for 3 hours. The reaction mixture was evaporated. The residue was crystallized from a mixture of hexane and methylbenzene. The product was filtered off and dried, yielding 5.3 parts (96.3%) of 6-chloro-8,9-dimethyl-9H-purine (intermediate 173).
Example 32
A mixture of 4.76 parts of g-chloro-N'methyl-4,5-pyrimidine- diamine and 7.2 parts of urea was stirred and heated for 1 hour at 180°C. After cooling, the residue was suspended in water. The product was filtered off and dried, yielding 3.3 parts (60%) of §-chloro-9-methyl-9H-purin-8-ol {intermediate 174).
Example 33
A mixture of 9.5 parts of 3-(2-chloroethyl)=-2,6-dimethyl-4H- pyrido[l,2-a]-pyrimidin-4-one, 160 parts of methanol and 40 parts of 2-propanol saturated with hydrogen chloride was hydrogenated at normal pressure and at room temperature with 2 parts of palladium- on-charcoal catalyst 10%. After the calculated amount of hydrogen } was taken up, the catalyst was filtered off over Hyflo and the . 25 filtrate was evaporated, yielding 9.5 parts (86%) of 3-(2-chloro- ethyl)-6,7,8, 9-tetrahydro-2,6-dimethyl-4H-pyrido(1,2-alpyrimidin-4-one monohydrochloride {intermediate 175).
In a similar manner there were also prepared: 3-(2-chloroethyl) 6, 7,8, 9-tetrahydro=2,6,8-trimethyl-4H-pyrido[l, 2-al= pyrimidin-4-one monohydrochloride (intermediate 176); 3-(2-chloroethyl)~6,7,8, 9-tetrahydro-2, 7-dimethyl-4H-pyrido(l, 2-alpyri- midin-4-one monohydrochloride (intermediate 177}. 3s
. . ey -) -45-
B. Preparation of Final compounds.
Example 34 :
A mixture of 5.52 parts of 6-(2-bromoethyl)-3,7-dimethyl-5B- thiazolo[3,2-a]pyrimidin-5-one monohydrobromide, 7.3 parts of 1-{(4-fluorophenyl)methyl)-N-(4-piperidinyl)-1B-benzimidazol-2-amine dihydrobromide, 6.4 parts of sodium carbonate and 135 parts of
N,N-dimethylformamide was stirred and heated overnight at 70°C. The reaction mixture was poured onto water. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The ‘ 10 residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (94:6 by volume), saturated with ammonia, as eluent. The pure fractions were collected and the co eluent was evaporated. The residue was crystallized from acetonitrile, yielding 5 parts (62.8%) of 6-[2-[4-[[1-[(4-fluorophenyl)methyl]- } 15 1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dimethyl-5B- thiazolo[3,2~a]pyrimidin-5-cne; mp. 141.0°C (compound 1).
Following the same procedure and using equivalent amounts of the ‘ appropriate starting materials, there were also prepared: }
Lo : : rl . : ! 2 ~
Het-CH, CH, -N NE 4 et | 23
N 237 omp » 1 1_,2_,3_,4 base or mp.
No. Het R A"=A"-A"=A salt form °C , ° 2 I - 4~F-C H, ~CH,= -CH=CH-CH=CH~ H,0 222.6 fm 0 N ~~ 3 od 4-F-C H, —CH, = -CH=CH-CH=CH~ base 190.7 . i AN ah ' : .
- : or Uileys -46- omp . 1 1_,2_,3_,4 base or mp.
No. Het . R AT=A"-A"=A salt form °C
N._CH > 1s Qf ? 4=F~C,H ~CH,- ~-CH=CH-CH=CH- JBCi®
X_N 6 4=""2 28,0 237.3 ‘ 0 co ASH : 10} 5 x 2-furanyl- ~CH=CH~CH=CH~ base 108.1 ' methyl~ : :
ZN CH, 6 gg! 2-furanyl- -N=CH-CH=CH- base 202.4 methyl- 15 cH, 7 x. J 4-F-C BH, ~CH,~ -N=CH-CH=CE- base 99.7 20 0 h “FO 8 CA - 4-F-CgH,~CH,~ =-CH=CH-CH=CH- pase 222.7
CH, O 25 3
Ss __N_ CH, 9 | IT | 2-furanyl- -CH=CH-CH=CH- H,0 129.1 i 3 i methyl- 30
S._N. CH,
J TI J-furanyl- -N=CH-CH=CH- pase 127-4 3 i methyl- ce am mm re om mm mm mm mo Sm mS SES TT
: trys -47- .
Comp . Het rt alan? a3? base or mp.
No. salt form °C i's
N N 0
Y
11 t, N- 2-furanyl- -CH=CH-CH=CH- base 258.0 1 methyl
H 0 3
CH . 3
N N oO : 10 lL I Y 2HC1 4-F-C_H -CH_=- -N=CH-CH=CH- : 12 x N- ela 2 CH-CH=CH H,O 196.1
CH 0 3 ~ CH, 13 | 2-furanyl- -CH=CH~-CH=CH- base 107.4 methyl . 1. ; ads 201 14 N | 2-furanyl- -N=CH-CH=CH- base 161.2] methyl ) ~N Hy 15 4-F-C_H ,-CH_~ ~CH=CH-CH=CH- 3HC1 229.1 : 6 4 2 24,0 .. : s__N_ CH } 16 N 4-F-C_H,-CH = -N=CH-CH=CH~ 3HC1 239.3 - 30 ’ Ss N_CH (7 ’ . 17 N 4-F-C H —CH,- ~-CH=CH~CH=CH~ base 241.1 ’ oO . 35 re SSS S SSS SoSooSSESomTEmTTTT . | .
C, ls -48-
Comp. 1 slon2_adoad base or mp.
No. Het R A-=h salt form °C
S N H ry° 18 N | 2-furanyl- ~CH=CH-CH=CH~ base 224.5! methyl
N_ CH z YY 3 19 ~ UN : 4~thiazolyl- ~CH=CH-CH=CH- base 167.1 methyl } . Z N CH, 20 CH — XN 2-furanyl- -N=CH~CH=CH- base 221.0 3 methyl ~ N CH, 21 c1 AN_N 2-furanyl- -N=CH-CH=CH- base 219.7 methyl oO - 30 . . 8 vot " p 3s
Flt (4 ~49-
Example 35
A mixture of 3.34 parts of 3-(2~chloroethyl)-2-methyl~4H-pyrido- [1,2-a}pyrimidin-4-one, 6 parts of 3-(4-fluorophenylmethyl)-N-(4~ piperidinyl)-3H-imidazo[4,5-b)pyridin-2-amine dihydrochloride, 4.8 parts of sodium carbonate, 0.1 pasts of potassium icdide and 135 parts of N,N-dimethylformamide was stirred and heated overnight at 70°C. The reaction mixture was poured onto water. The product was : extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column-chromatography over gilica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (96:4 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile, yielding 4 parts (60%) of 3-[2- {4-[ [3- [ (4-£luorophenyl)methyl]-3H-imidazo(4,5-b)-pyridin-2-yllamino]- 1-piperidinyl]ethyl)-2-methyl-4H-pyrido(l,2-alpyrimidin-4-one dihydrochloride; mp. 195.7°C (compound 22). ‘ In a similar manner there were also prepared:
Rr 1
AO oh
N 2s
Fr eT 23 N(CH), 4-F-CgH,~CH,= -CH=CH-CH=CH- ho 226.9 o :
H :
N 0 24 fe ) 2-furanyl- ~-CH=CH-CH=CH- base 238.4 2°2 methyl oO as vl i . so ' . h oe Ce & ~50- omp . L ry aloaZ-pdant base or mp.
No. salt form °C
H
TY
25 A Jen, 4-F-CH ~CH, -N=CH-CH=CH~- H,0 251.6 a . } H hd 26 2-furanyl- . =N=CH-CH=CH- base 231.7 (CH) 2°2 methyl 0 i hg Hy ‘ 27 (CH_) 4-F-C H,~CH~ ~CH=CH-CH=CH- base 115.1 2°2 0
SS H, 28 ( | CH.) 2-furanyl- -N=CH~CH=CH- base 186.4 2°2 methyl 0 : H
N oO x T 29 N(CH), 4-F-C_H -CH,= ~CH=CH-CH=CH- base 245.3 . 0 cL H ‘ N 0 30 T.. ) 2-furanyl- ~-CH=CH-CH=CH- base 250.7 2°3 methyl 0 ~~" CH, 31 I | (cn, 2furanyl- —CH=CH-CH=CH- base 103.6 2°2 methyl
Oo : 30 H
N oO “TY .0 - - -N=CH-CH=CH~ 234. 32 ~ (CH_) 2-furanyl C base 2°3 methyl
Jal -51-
Comp. L re alap2-p3an? base or mp.
No. . salt form °C = ° 2HC1 33 weeny). 4F CEH, CH, CH=CH-CH=CH- = 207.1 22 2
CH
. | 3
N 0 34 T.. ) 2-furanyl- ~CH=CH~CH=CH- base 217.4 2°2 methyl
CH
3
N
35 (CH) 2-furanyl- ~N=CH-CH=CH~ base 185.0 22 methyl
CH : 4 3 : : i : N__O }
Y 4-F-C H-CH_- ~N=CH-CH=CH- 91. 36 N(CH.) 5 ic 2 CH=CH 2HC1: 291.2 2°2 i H Co
Co Yt ‘ . -F- - —~N=CH-CH=CH- 236, 37 N(CH.) 4-F CgHZCH, N=CH-CH=C H,0 36.1 po 2°3 : . oo . 2 , ( FY CH vr . -F- - -N=CH-CH=CH- 2HC 259.6 38 N (CH) 4-F CgHaCH, C 1 . 2°2
So CH 0 . 30 3X N 39 2-furanyl- -CH=CH-CH=CH- base 192.0
H_C-N N 3 (CH ) methyl ~ 0 2°2 . 5 H ,
SY ; -F-C H - - =CH=CH-CH=CH- 234. 40 SUN 4-F Ce 4 cH, base
7 Le lef3 . -52- mm mmo omp. rl al=aZ.a3-a4 base or mp.
No. L A salt form °C
N. CH
Co : 5 | Zo 2 5 4—-F- - - -CH=CH-CH=CH- ase . 41 NY F Cely CH, CH=CH-CH=CH 196.6 . i H i's oO N 3 42 H.c- | N(CH.) 2-furanyl- ~N=CH~CH=CH- base 195.3 | 3 2°2 methyl . ; CH 3 0. _N "N ' 2HBr 43 Hu J | N(CH_) 4-F-C_H,~CH = ~N=CH-CH=CH- HO 246.6 3 2°2 2 0
N H
~ 3 3nC1 44 N CH.) 2~furanyl- -CH=CH-CH=CH- 36.0 211.2 272 methyl 2 ©
CH, as | 4-F-C H -CH_- -CH=CH-CH=CH- HCl 223.2] : (CH) 6 4 2 2H, O 22 2 oO
NSH, 7 -F-C_H -CH_- -N=CH-CH=CH- 204. ; 46 (Jen F Ce 4 C 5 H C base ° : 47 2-furanyl- ~N=CH~CH=CH- base 177.8
N CHy) ethyl
Ss N Hy . y - 1 48 T CH.) 2-furanyl- ~N=CH~CH=CH- base 153.8 ! 2°2 methyl bm mmm mmm mm mm mmm mmm mmm mmm
I
: 6 73 -53- mw omp. L rl al=a2-p3-p4 base or mp.
No. salt form °C , 5 ae | H, oo 49 kt 4-F-C_H,-CH,- -CH=CH-CH=CH- base 187.1 ' or ’ y N CH, 7 4-F-C_H -CH_- -CH=CH-C=CH- 68.7 50 CY CH.) PLA 5 CH=C C=cH base 1 | 2°2 . | CH, !
N_ CH : 2 3 ‘51 SUN CH ) 3-pyridinyl- -CH=CH-CH=CH- base 205.1 ' 22 methyl = N Hy 52. UN CH ) 2-thienyl~ -CH=CH~-CH=CH- base 219.4 2 2 methyl 0 . 20 CH .
Zz No 3 53 ~ UN CH) 4-F-C_H CH, ~CH=CH-N=CH- base 222.3 2°2 0
FN
EY N CH.) 2-furanyl- -N=CH-CH=CH- base 175.6 2’2 methyl ;
CH, i
NCH
Cx 3 55 2-pyridinyl- ~N=CH-CH=CH- base 207.3 x
N CH,Y, methyl
N._ CH : z ~ 3 : 56 2-pyridinyl- -CH=CH-CH=CH-~ base 193.3 x (CH) . 2°2 methyl 3s 0 " em mmm i . 1 oC
Hee y3 * . -54- omp . L rR} al=a2-pa3a4 base or mp.
No. salt form °C
N H
” 3 57 & | CH) 2-pyridinyl- -CH=CH~CH=CH~ base 193.8 2°2 methyl 0 - z CH, 58 . | yy 2-furanyl- -N=CH-CH=CH- base 208.4 cu 2° 2 methyl 3
CH, 59 2-thienyl- -CH=CH~CH=CH- base 214.0
N (CH) 2° 2 methyl 0
N Hy : 4-F~C_H -CH_- ~CH=CH-N=CH~- . 60 N CH.) 6a 2 CH=CH~-N=CH base 230.5 2°2 20 .
N H
Zz 3 —f- - - -N=CH~ == -— . 61 N CH.) 4-F CeHy CH, CH-CH=CH base 166.0 2°2
N Hu <r 3 62 ll oq, 4-thiazolyl- -CH=CH-CH=CH- base 158.8 2°2 methyl
CH
’ 3 , 30 MN Hy 63 2-furanyl -N=CH~CH=CH~ base 86.2 . N (CH.) methyl
Qe«3 -55—~ omp. 1 1__.2 3 4 base or mp .
L R A"=A -A"=
No. A“=h salt form °C
H oO “ 64 SN (cn) A4-thiazolyl- ~CH=CH-CH=CH- base 239.5 2 2 methyl
AN CH, 65 (CH.) 3-pyridinyl- -CH=CH~CH=CH- base 235.1 2°2 methyl ! ; H . ! N 0 “7 ‘ 66 ~ CH.) 2-pyridinyl- ~-CH=CH-CH=CH- base 238.8 { 2°2 methyl ! 0 i H
N._-©O ‘ 7 t 67 CY (CH) 2-pyridinyl- -N=CH-CH=CH- base 240.2 2° 2 methyl t : , } .
LEE .
Example 36 ®
A mixture of 3.15 parts of 3-(2-chloroethyl)-2-methyl-4H- ‘ pyrido[l,2-alpyrimidin-4-one, 8.26 parts of N-(4-piperidinyl)-1-
B (2-pyrazinylmethyl)-1H-benzimidazol-2-amine trihydrobromide, 6.4 : 25 : = oo . parts of sodium carbonate, 0.1 parts of potassium iodide and 90 ’ parts of N,N-dimethylacetamide was stirred and heated overnight at 80°C. The reaction mixture was poured into water. The product was extracted with trichloromethane. The extract was dried, filtered and } , evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, ’ saturated with ammonia, (96:4 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue . was crystallized from acetonitrile. The product was filtered off and dried, yielding 5 parts (67.4%) of 2-methyl-3-(2-{4-[[1-(2-pyrazinyl- f
Sey; -56- methyl) -1H-benzimidazol-2-yl] amino)-l-piperidinyl]ethyl]-4H-pyrido- [1,2-a)pyrimidin-4—~one; mp. 204.4°C (compound 68).
In a similar manner there were alsc prepared: 1 . i al 2 . N A (1 ke
A zz a —_—
Comp. 1 1_,2 ,3_,4 base or mp.
No. L R A7=h -A =A salt form °C
CH . oo (Y 3 . 69 (CH,), 4-Cl-C H,~CH,= -CH=CH-CH=CH- base 208.0 i 15] or Hy : 70 SU (CH, , 4-F-C_H ,~CH,~ -CH=CF~CF=CH- base 132.3
N CH, 2HC1 | 71 (CH, , CH, CH, = CH=CH-CH=CH 1/2H,0 225.9 ' : N. CH
Cr 3 ‘ | 72 QU KN CH,), H -CH=CH~CH=CH~ base 238.5
N CH
73 QQ. (CH,), cyclohexyl ~-CH=CH-CH=CH- base 156.2 a, NCH, j ) 74 x ( CH,) ,2-furanyl- ~N=CH~-CH=CH~ H0 153.3 0 methyl
N CH
Zz ~ | 3 75 WN CH,), 2-furanyl- -N=CH~CH=CH- base 175.8 methyl : H 3 meme { i .
’ | Vig -57-
Comp. L rl al=a2-p3=p4 base or mp.
No. salt form °C . pZ NX CH, 76 CF Lea, 2-furanyl- -N=CH~CH=CH- H,0 218.3
Br 8 methyl ke) NCH, * ~ 77 Cr | (cH,), 2-furanyl- -N=CH-CH=CH- H,0 140.6 methyl
CH
3
NCH, "ol 78 (OF Xan, 4-F-C H ~CH, = ~CH=CH-C=CH~ base 192.8 : d cH, i = N CH, ‘ 7 » 3 HCl 15: | ~F- -CH_~ ~CH=N-CH=CH- 51.6 79 CF Joes, 4~F CeHy CH, CH=N-CH=CH 5 HO 251. : H ! N { = 2-thienyl- -CH=CH-CH=CH- b 243.4 80 Jen methyl CH=CH~-CH=CH ase z N__ CH,
Zz 2-thienyl- -N=CH-CH=CH- b. - i Bl CF Jew, methyl ase | A~2V CH, 3-furanyl- : ~N=CH-CH=CH- base - 82 AN CH) 5 methyl ~ NCH, : z , 5-methyl- -N=CH-CH=CH~- base - | 83 CF Je, 2-furanyl- methyl . 2-thienyl-
CH -N=CH-CH=CH- base - 84 N ¢ 22 methyl ‘ . : RE . r
: Coteqs i \ J . 1! . , . cL -58-
Comp. L rl al=a2-a3-at base or mp. : No. : salt form °C 3-furanyl- . 85 N (CH,), methyl ~N=CH-CH=CH- base - - .
ZN | CH, 5-methyl- 86 CH,), 2-furanyl- -N=CH-CH=CH-~ base - : methyl : wy 2-thienyl- 87 CX Len, methyl ~N=CH-CH=CH- base - : H
N Oo | Y 3-furanyl- _ - 88 CI fio. methyl N=CH-CH=CH base -
H
~¢° .
S~methyl- HCH _ 89 CL Le, 2-furanyl- N=CH-CH=CH base . 20 methyl
In a similar manner there were also prepared: 3-[2-{4-[ [1 [(4~fluorophenyl)methyl]-1H-benzimidazol-2-yl] (phenyl- methyl)amino]-1-piperidinyllethyl]-6,7,8,9-tetrahydro-2-methyl-4H- i pyrido(l,2-alpyrimidin-4-~one (E)-2-butenedioate(1l:1)7 mp. 186.4°C (compound 90): 3-{2- [4-[ [1-[ (4-fluorophenyl) methyl] -1H~benzimidazol-2-yllmethyl- amino] -l-piperidinyl]ethyl]-2-methyl-4H-pyrido(l,2-a}pyrimidin-4-one trihydrochloride; mp. 244.7°C (compound 91); and cis-3-[2-[4-[[1-[(4-fluorophenyl)methyl]~1H-benzimidazol-2-yl]amino}- 3-methyl-1l-piperidinyl] ethyl] -2-methyl-4H-pyrido(l,2-alpyrimidin-4- one; mp. 160.6°C (compound 92). ro . . . " fi
Ss le 7 -59-
Example 37
A mixture of 2 parts of 6-chloro-9H-purine-9-ethanol, 3.7 parts of N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H~ benzimidazol-2-amine, 1.06 parts of sodium carbonate and 45 parts of
N:N-dimethylacetamide was stirred and heated for 3 hours at 130°C.
The reaction mixture was poured into water and the product was extracted with 4-methyl-2-pentanone. The extract was dried, filtered and evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 2.8 parts (53%) of 6-[[2- [4- [ [1-[ (4-f Luorophenyl) methyl] -1H-benzimidazol-2-yl]amino]-1- piperidinyl]ethyl]}amino]-9H-purine-9-ethanol; mp. 168.7°C {compound 93).
In a similar manner there were also prepared:
R’ "ye
R" N N R = x N CHy ~N 1
Lo ALR? : NH-CH. CH ,-N NH A bas ; 2M T [ER oo N Adz } : . 20 :
Comp. gt R" R"' al=aZ-a3-at pa 0. Cc
St : 94 CH, H 4-fluoro ~CH=CH-CH=CH- 188.0 95 C_H.CH H 4-f luoro -CH=CH-CH=CH- 145.5 . : 96 CH, CH, 4~-fluoro -CH=CH-CH=CH- 211.7 i 97 H H 4-fluoro ~-CH=CH-CH=CH- 151.4 a8 CH, OH 4-fluoro -CH=CH-CH=CH~- 257.1 99 CH, H 3-CH, ~CH=CH~-CH=CH- 188.9 100 CH, H H —-CH=CH-CH=CH- 207.5 101 CH, H 4-f luoro -CH=C~CH=CH~- 194.5 [
OCH, 102 CH, H 4~f luoro ~CH=CH~-C=CH- 186.1
OH a '
Lele 43 -60-
Example 38
A mixture of 2.8 parts of 2-(methylthio)thiazolo(5,4-blpyridine and 5.5 parts of N-[1-(2-aminoethyl)-4-piperidinyl]-1-((4-fluoro= phenyl)methyl]-1H-benzimidazol-2-amine was stirred for 24 hours at § 140°C. The reaction mixture was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (97:3 by volume) as eluent. The pure . fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 1.9 parts (25%) of N-[2-[4-[[1-[(4-fluorophenyl)- methyl]-1H-benzimidazol-2-yl]amino]~1-piperidinyljethyl]thiazolo= (S,4-b]pyridin-2-amine; mp. 203.5°C {compound 103).
In a similar manner there was also prepared: §-(2- [4-1 [1-[ (4-£ Luoropheny 1) methyl] -Li-benzinidazol-2-y1] amino] -1- piperidinyllethyl]thiazolo(4,5-c]pyridin-2-amine; mp. 192.6°C (compound 104).
Example 39 . A mixture of 2.5 parts of thiazolo[5,4-blpyridine-2-thiol, 1 part of a sodium hydride dispersion 50% and 45 parts of N,R-dimethyl- formamide was stirred for 1 hour. Then there was added a solution of ; 6.9 parts of N- [1-(2-chloroethyl)~4-piperidinyl]-1-(4-fluorophenyl- methyl) -1H-benzimidazol-2-amine in 45 parts of N,N-dimethylform- . amide. The whole was stirred overnight. Water was added dropwise.
The product was extracted with 4-methyl-2-pentanone. The extract was ‘ : 25 dried, filtered and evaporated. The residue was purified by column : chromatography over silica gel using a mixture of trichloromethane oo : and methanol, saturated with ammonia, {95:5 by volume) as eluent.
The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 0.5 parts (6.4%) of 1-{(4-fluorophenyl)- methyl] -N-[1- [2-(thiazolo[5,4=blpyridin-2-ylthio)ethyl]-4-piperi- ’ : dinyl)-1H-benzimidazol-2-amine; mp. 159.9°C (compound 105).
Example 40
To a stirred and cooled (0°C) mixture of 3.8 parts of poly{oxy-
’ of Cle 3 . n . -61- methylene) 37%, 15.5 parts of 1-((4-fluorophenyl)methyl]-R~ (4-piperidinyl)-1H-benzimidazol-2-amine and 7 parts of glacial acetic acid were added 6.5 parts of 2-methylimidazo[l,2-a)pyridine under nitrogen atmosphere. The whole was heated slowly to 50°C and stirring was continued at 50°C for 2 hours. After stirring was continued overnight at room temperature, the reaction mixture was poured into water and the whole wis made alkaline with sodium hydroxide. The product was extracted with dichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (96:4 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 6.7 parts (30%) of 1- {(4-fluorophenyl)methyl] -N-[1-{(2-methylimidazo(l,2-a]pyridin-3- ’ y1)methyl]-4-piperidinyl]-1H-benzimidazol-2-amine; mp. 198.1°C (compound 106).
Example 41
To a stirred mixture of 5.3 parts of 4-[l-(4-fluorophenylmethyl)- 1H-benzimidazol-2-ylamino] -1-piperidineethanol dihydrochloride, 2.8 parts of a sodium hydride dispersion 50% and 90 parts of N,N-di- methylformamide were added 2.55 parts of 2-(methylsulfonyl)thiazolo~ . (5,4-bl pyridine. The whole was stirred for 2 hours. The reaction mixture was poured into water. The product was extracted with 4-methyl-2-pentanone. The extract was dried, filtered and ) evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane, hexane and methanol . {45:45:10 by volume) as eluent. The pure fractions were collected ’ ’ . and the eluent was evaporated. The residue was crystallized from oo to 30 acetonitrile. The product was filtered off and dried, yielding 0.9 a parts (15%) of 1-{( 4-f1uorophenyl)methyl] -N-[1-[2-[(thiazolo[5,4-b}= pyridin-2-yl)oxylethyl]-4-piperidinyl]-1H-benzinidazol-2-anine; ' ) mp. 151.0°C (compound 107). as
Co L lef : Ki -62-
Example 42
A mixture of 8 parts of N-{2-[4~[{1- [(4-fluorophenyl)methyl]- 1H-benzimidazol-2-yl]amino]-1-piperidinyljethyl]}-N'~[4-(methyl- amino) -3-pyridinyl]lthiourea, 15 parts of mercury(IX)oxide, 0.1 parts of sulfur and 120 parts of ethanol was stirred and refluxed for 3 hours. After the addition of another 15 parts of mercury(II)oxide, stirring at reflux was continued for 2 hours. The reaction mixture was filtered over Hyflo and the filtrate was evaporated. The residue hy was purified by column chromatography over silica gel using a en 10 mixture of trichloromethane and methanol saturated with ammonia to : ’ (95:5 by volume) as eluent. The pure fractions were collected and : Co the eluent was evaporated. The residue was crystallized from ’ acetonitrile. The product was filtered off and dried, yielding 4.4 : parts (59%) of N-{[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol~ 2-yl}amino}-l-piperidinyljethyl]-1-methyl-1H-imidazo[4,5-c]pyridin- 2~amine monohydrate; mp. 144.6°C (compound 108).
In a similar manner there were also prepared: r! 1
INL
Het-NH-CH_-CH_-N NH = 22 | 3
A ay
Fomp. 1 1_,2_,3_,4 base or mp.
No. Het R A"=R =A =A" salt form °C :
H
N i 109 FIT 4-F-C_H, ~CH,- -CH=CH-CH-CH- base 250.5!
N ! . : i | H i “2 N } - 110 T 4-F-C_H -CH_- =CH=CH-CH=CH- base 259.3 ~ 6 4 2 :
N .
H
N
|111 qn 2-furanyl- ~-CH=CH-CH=CH- base 229.8 i NX N methyl mmm mem mmm mmm mm mm mm mmm mm mm mmm bo 2
Cu iW : A if c tH v 5 ! r -
. . Hotel Te -63-
Comp . 1 1 2 3 4 base or mp.
R A"=A -A =A
No. Het salt form °C
H .
A~¢N 2 ( I —F- _CH — ~-CH=CH-CH=N- base 276.7 s | 1 | hl 4-F-C H,~CH,
H
N
113 T 2-pyridinyl -N=CH-CH=CH- base 243.0 methyl
N
114 ( I T 4-F-C_H,-CH,~ =-N=CH-CH=CH- 4(COOH) , 238.8 x N
H
N
115 “1 T 2-pyridinyl - -CH=CH-CH=CH- base 233.0 ' NX methyl a. 20 H
N
116 Zz T phenyl —CH=CH-CH=CH- base 212.6 . : i Nx
H ‘
AN
117 T 2-thienyl- —CH=CH-CH=CH- base 232.6
NX methyl
H
NZ N
|118 L ar 4-F-C H,~CH - —CH=CH-CH=CH- base 265.6 .
N
H
~~" (E) 119 T 2-furanyl- ~N=CH-CH=CH- ui coou) 169.0 2 \
NX methyl (1:3). 0 . r
CE - 2 CeCe Z -64- we © otal Tt en 120 CIT 4-F-C_H ,~CH,- ~-CH=CH-CH=CH~ base 219.9 x -
A mixture of 18 parts of N-(4-amino-3-pyridinyl)-N'-(4-{4-([1- {(4-fluorophenyl) methyl] -1H-benzimidazol-2-yl]amino])-1-piperidinyl]- . butyl)thiourea, 7 parts of mercury(II)oxide, 1 part of sulfur and . 180 parts of tetrahydrofuran was stirred and refluxed for 5 hours.
The reaction mixture was filtered hot over Hyflo and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol saturated with ammonia, (90:10 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of tetrahydrofuran and trichloro- methane, yielding 5 parts (29%) of N-[4-[4-[ [1-[(4-fluorophenyl)- methyl) -1H-benzimidazol-2-yl}amino] -1-piperidinyl]butyl] ~1#-imidazo- (4,5-c)pyridin-2-amine; mp. 228.2°C (compound 121). ' ' In a similar manner there were also prepared:
N-[3- [4-[ [1- [(4-f Luorophenyl)methyl] ~1H-benzimidazol-2-y1} amino] -1- piperidinyl}propyl]-1H-imidazo[4,5-clpyridin-2-amine ethane- dioate(2:7); mp. 220.4°C (compound 122): and
N-[2- [4 [ [1- [{4-£luorophenyl)methyl] -1H-benzimidazol-2-yl]amino]-1= piperidinyl]ethyl]-3-methyl-3H-imidazo[4,5-c]pyridin-2-amine ethane- diocate{(1l:3) monohydrate; mp. 242.3°C (compound 123). ) : Example 44
To a stirred mixture of 7.7 parts of 2-(ethylamino)-N-(2-{4-{[1- > [(4-£luorophenyl) methyl] -1H-benzimidazol-2-yl]amino] -1-piperidinyl}- ethyllbenzamide, 2 parts of N,N-diethylethanamine and 90 parts of tetrahydrofuran were added dropwise 1.6 parts of ethyl carbono~- 1 35 ee . oo : ; . | g
Co Cd
: ~ Ue : -65~- chloridate. Upon completion, stirring was continued for 1 hour at room temperature. The reaction mixture was evaporated and 4-methyl- 2-pentanone was added to the residue. The organic phase was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractions were collected and the &luent was evaporated. The residue was further purified by HPLC using a mixture of methylbenzene and ethanol (90:10 by volume) as eluent. The pure fraction was collected and the eluent was evaporated. The residue was crystallized from acetonitrile, yielding 2.2 parts (25%) of ethyl {1-[2-[l-ethyl-1,4~ dihydro-2, 4-dioxo-3(2H)-quinazolinyl]ethyl] -4-piperidinyl]-{1-[(4- f£1luorophenyl)methyl] -1H-benzimidazol-2-yl] carbamate: mp. 160.3°C (compound 124}.
Example 45 .
To a stirred mixture of 4 parts of 2-(ethylamino)-N- [2- [4-[[1- {(4-f Luorophenyl)methyl] -1i-benzimidazol-2-yl]amino] ~1-piperidinyl]- ’ ethyl) benzamide, 1.06 parts of sodium carbonate and 65 parts of dichloromethane was added dropwise a solution of 2 parts of methyl carbonochloridate in dichloromethane. Upon completion, stirring was continued overnight at reflux temperature. Water was added and the product was extracted with dichloromethane. The extract was dried, , vo filtered and evaporated. The residue was purified by column ’ . chromatography over silica gel using a mixture of trichloromethane ‘ and methanol (90:10 by volume) as eluent. The pure fractions were : collected and the eluent was evaporated. The residue was converted } into the hydrochloride salt in acetonitrile and 2-propanol. The salt was filtered off and dried, yielding 1.8 parts of l-ethyl-3-(2-{4- (1- [(4-F Luoropheny1)methyl] -1i-benzinidazol-2-yl) amino) ~1-piperi- dinyl)ethyl]-2,4(1H,3H)-quinazolinedione dihydrochloride; mp. +260°C (compound 125).
Example 46
A mixture of 6 parts of 2-amino-N-[2-[4-[{1-[(4-fluorophenyl)- pethyl]-1i-benzinidazol-2-yl]anino] -1-piperidinyl]ethyl]-5-(methyl” thio)benzamide, 1.78 parts of 1,1'-carbonylbis[1H-imidazole] and 90
Slee v3 -66- parts of tetrahydrofuran was stirred and refluxed overnight. The reaction mixture was evaporated. The residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 5.2 parts (85%) of 3-[2-([4-{[1-[(4-fluorophenyl)methyl]-1H~-benzimidazol- 2-yl)amino]l-l-piperidinyllethyl]-6-(methylthio)-2,4(18,3H)-quina- } Co zolinedione; mp. 238°C (compound 126).
In a similar manner there were«also prepared: . 3-[4-[4=[ (1~[(4-f luorophenyl)methyl) -1H-benzimidazol-2-yl]amino]-1- piperidinyl]butyl}-2,4(1H,3H)-quinazolinedione; mp. 212.6°C (compound 127); and 3-[4-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl)amino}-1-~ : piperidinyl]-butyl]}-2,4(1H, 3H)-quinazolinedione; mp. 194.3°C {compound 128).
Example 47 oo
To a stirred mixture of 4.7 parts of N-[2-{4-[[1-(2-furanyl- methyl)-1H-benzimidazol~2-yl]amino] -1-piperidinyl]ethyl] -2-(methylamino)- benzamide, 2.02 parts of N,N-diethylethanamine and 195 parts of dichloromethane was added dropwise a solution of 1.14 parts of carbonothioic dichloride in dichloromethane. Upon completion, ! stirring was continued overnight at room temperature. The reaction . mixture was poured into water. The layers were separated. The ; organic layer was dried, filtered and evaporated. The residue was
So purified by column chromatography over silica gel using a mixture of oo trichloromethane and methanol, saturated with ammonia, (96:4 by " 25 volume) as eluent. The pure fractions were collected and the eluent : : was evaporated. The residue was crystallized from acetonitrile, yielding 1.4 parts (27.5%) of 3-[2-[4-[{1-(2-furanylmethyl)-1H- ) benzimidazol-2-yl]amino}-1-piperidinyl]ethyl]-2,3-dihydro-1- : methyl-2-thioxo-4(1H)-quinazolinone; mp. 188.4°C (compound 129). . 30 In a similar manner there was also prepared: 3-2 [4-[ [1-[ (4-fluorophenyl) methyl] -1H-benzimidazol-2-yllamino]~1- ~ piperidinyl]ethyl]-2,3-aihydro-1-methyl-2-thioxo-4(1H)-quinazolinone: mp. 215.8°C (compound 130).
A ,
FG v3 -§7-
Example 48
To a stirred solution of 10.9 parts of N-[1-(2-aminoethyl)-4- : piperidinyl]-1-(4-fluorophenylmethyl)-1H-benzinidazol-2*anine in 150 parts of tetrahydrofuran was added dropwise a solution of 6 parts of methyl 2-isothiocyanatobenzoate in 30 parts of tetrahydrofuran at room temperature: slightly exothermic reaction, the temperature rose to 30°C. Upon completion, stirring at room temperature was continued for one hour. The reaction mixture was evaporated. The residue was stirred in trichloromethane. The formed precipitate was filtered of f and crystallized from 2-propanone. The product was filtered off and
RE dried, yielding 5.2 parts of 3-[2-[4-[1-(4-fluorophenylmethyl)-1H- benzimidazol-2-ylamino]-1-piperidinyllethyl]-1,2-dihydro~2-thioxo- 4(3H)-quinazolinone; mp. 198.5°C (compound 131) -
In a similar manner there were also prepared: } 15 3-[2- [4- [ [1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino}-1- piperidinyllethyl]-2,3-dihydro-2-thioxo=4(1H)-quinazolinone; mp. , 146.0°C (compound 132); ; 3-[2-[4- [ (1-[(4-fluorophenyl) methyl] -1H-benzimidazol-2-yllamino]-1- ; . piperidinyl]ethyl]~2,3-dibydro-6-methyl-2-thioxothieno(2,3-d]= pyrimidin-4(1H)-one; mp. 236.4°C (compound 133); and : 3-({2-[4-[ [1-(2-furanylmethyl)-1i-benzimidazol-2-yl) amino} -1-piperi- dinyl]ethyl]-2, 3-dihydro-6-methyl-2-thioxothieno(2,3-d]pyrimidin- 4(1H)-one monohydrate: mp. 214.5°C (compound 134). ] Example 49 } : 25 To a stirred mixture of 4.1 parts of 3-[2-(4~[[1-{(4-fluoro- phenyl)methyl] -1H-benzimidazol-2-yl]amino] -1-piperidinyl]ethyl]=2,3- dihydro-6-methyl-2-thioxothieno[2,3-dlpyrimidin-4(1H)-one, 5.6 parts of potassium hydroxide, 81 parts of ethanol and 8 parts of water . were added dropwise 60 parts of a hydrogen peroxide solution 3%. The whole was stirred overnight. The reaction mixture was evaporated.
The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol {90:10 by volume) as eluent. The pure fractions were collected and the eluent was : evaporated. The residue was crystallized from 2-propanone. The product was filtered off and dried, yielding 2.2 parts (55%) of
NP Lbys : -68- 3-[2-[4-[{1- [(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1~ ) piperidinyl]ethyl]-6-methylthieno[2,3-d]pyrimidine-2,4(1H, 3#)-dione; mp. 187.6°C (compound 135). " In a similar manner there was also prepared: ' 5 3-[2- [4-{ [1-(2-furanylmethyl)-1H-benzimidazol-2~yl]amino]-1-piperi- . dinyl]ethyl]-6-methylthieno{2,3-d]pyrimidine-2, 4(1H, 3H) dione; mp. oo 151.7°C (compound 136). - oo Example 50 . A mixture of 4.86 parts of 2-amino-N-[2~[4-[(1-[(4-fluorophenyl)~- methyl] -1H-benzimidazol-2-yl]amino]-1-piperidinyljethyl]benzamide, 1.4 parts of formic acid and 45 parts of methylbenzene was stirred and refluxed overnight. The reaction mixture was evaporated and the residue was taken up in trichloromethane, water and ammonium hydroxide. The organic phase was separated, dried, filtered and evaporated. The residue was crystallized from acetonitrile, yielding . . 3.6 parts (73%) of 3-[2-[4-([1-[(4-fluorophenyl)methyl]-1H-benz- imidazol-2-yl)amino]-1-piperidinyl]ethyl]}-4(3H)-quinazolinone; mp. : 190.6°C (compound 137).
Example 51
A mixture of 3.7 parts of 2-amino-5-(methylthio)benzoic acid and . 8.9 parts of N-[2-[4-[ [1- [(4-fluorophenyl)methyl) -1H-benzimidazol~ 2-yllamino)-1l-piperidinyl]ethyl}formamide was stirred for 5 hours at 150-160°C. The whole was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue . was crystallized from a mixture of 1,1'-oxybisethane and aceto- 4 nitrile. The product was filtered off and dried, yielding 4.5 parts (41.5%) of 3-[2-[4-[ [1- [(4-fluorophenyl)methyl] -1H-benzimidazol-2~ yllamino]-1-piperidinyl]ethyl]-6-(methylthio)-4(3H)-quinazolinone; mp. 101.4°C (compound 138). ) Example 52 :
A mixture of 3 parts of 2-amino-N- [2-[4~{[1-[4-flvorophenyl)- , methyl) -1H-benzimidazol-2-yl]amino) -1-piperidinyl]ethyl]benzenanide, : 35 20 parts of acetic acid anhydride and 40 parts of water was stirred trey -69- overnight at 120°C. The reaction mixture was cooled and ammonium hydroxide was added. The product was extracted with 4-methyl-2- pentancne. The extract was dried, filtered and evaporated. The residue was purified by columh chromatography over silica gel using a mixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractions were cgllected and the eluent was evaporated. The residue was crystallized from acetonitrile, yielding 2 parts (67%) of 3-[2-(4-{[1~[(4-£fluorophenyl)-methyl]-1H-benz- . imidazol-2-yl] amino] -1-piperidinyl]ethyl]-2-methyl-4(3H)-quinazoli~ none; mp. 185.5°C (compound 139). :
In a similar manner there-was also prepared: } 3-{2-[4[ [1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino] ~1-piperidi- nyllethyl)~-2-methyl-4(3H)-quinazolinone; mp. 155.7°C; (compound 140).
Example 53
A mixture of 8.85 parts of 2-amino-N-{2-(4-[[1-[4-fluorophenyl)- methyl] -1H-benzimidazol-2-yllamino] -1-piperidinyllethyl]benzenanide, 1.9 parts of ethyl 2-propynoate and 40 parts of ethanol was stirred and refluxed for 24 hours. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, . } . (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the (E)-2-butenediocate salt in ethanol. The salt was filtered off and dried, yielding 5.1 parts of ethyl 3-(2-{4-[{1-[(4-fluorophenyl)- nethyl]-ifi-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]=1,2,3,4- tetrahydro-4-oxo-2-quinazolineacetate (E)-2-butenedioate (1:2): mp. 195.6°C (compound 141).
Example 54 ’
A mixture of 3.2 parts of N-(2-[4-[[1-[4-fluorophenyl)methyl] 1H benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-1,2-benzenediamine, : 1.25 parts of 1,1'-bis[1H-imidazol-1-yl]methanethione and 45 parts of tetrahydrofuran was stirred overnight at room temperature. The reaction mixture was evaporated and the residue was taken up in 4-methyl-2-pentanone. The organic phase was washed twice with water, . 35 dried, filtered and evaporated. The residue was purified by column
Ley 3 -70~ chromatography over silica gel using a mixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystal- lized from acetonitrile, yielding 1.9 parts of 1-[2-[4-[[1-[(4- f£luorophenyl)methyl) ~1K-benzimidazol-2-yl]amino)~1-piperidinyl]ethyl}- 1,3-dihydro-2H-benzimidazole-2-tHione; mp. 235.3°C (compound 142).
Example 55 .
To a stirred mixture of 4.6 parts of N= [2-(4-[12-((4-fLuoro- ) heny1) methyl] ~1i-benzinidazol-2-y1] amino) -l-piperidinyllethyll-4, 5 pyrimidinediamine, 2.25 parts of N,N-diethylethanamine and 195 parts of dichloromethane were added dropwise 1.75 parts of carbonothioic . dichloride. Upon completion, stirring was continued for 3 hours at reflux temperature. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in ethanol and 2-propanol. The salt was filtered off and dried, yielding 1 part (15.4%) of 9-[2-[4-[[1-[(4-fluoro- phenyl )methyl]-1H-benzimidazol-2-yl] amino] -1-piperidinyllethyl]-7, 5 dihydro-8H-purine-8-thione trihydrochloride .dihydrate; mp. 244.7°C (compound 143). ‘ Example 56 7.5 Parts of g-chloro-N'-[2-[4~[[1-[(4-fluorophenyl)methyl]-1H~ benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-4,5-pyrimidinediamine . . and 3.6 parts of urea were heated together till about 220°C during ’ 10 minutes. The resulting melt was cooled and suspended in water.
The solid was filtered off, washed with water and ethanol and i . recrystallized from a mixture of N,N-dimethylacetamide, ethanol and ) 30 water, yielding 3.9 parts (49.9%) of 6-chloro-9-[2-[4-({1-[(4- ’ } fluorophenyl)methyl] ~1i-benzinidazol-2-yl]l amino] -1-piperidinyl]ethyl]- 7,9-dihydro-8H-purin-8-one; mp. 266.2°C (compound 144).
A
Del, 92, -71-
In a similar manner there was also prepared: 9-[2- [4- [ [1 (4-fluorophenyl)methyl] -1H-benzimidazol-2-yl]amino]-1= piperidinyl]ethyl]-7,9-dihydro-8H-purin=8-one; mp. 260.5°C; {compound 145).
Example 57
A mixture of 5 parts of ethyl ethanimidate hydrochloride, 9 parts of N° [2- [4- [[1- ((4-fluorophenyl)methyl] -1H-benzinidazol-2-y1] = amino] -1-piperidinyl]ethyl])-2,3,6-pyridinetriamine and 100 parts of acetic acid was stirred overnight at room temperature. The reaction - 10 mixture was evaporated. The residue was dissolved in trichloro- methane. Water was added and sodium hydrogen carbonate was added . till foaming had ceased. The layers were separated. The organic layer was dried, filtered and evaporated. The residue was purified by column~chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (95:5 by volume) as eluent. The pure fractions were collected and the eluent : was evaporated. The residue was crystallized from 2-propanone. The - . - product was filtered off and dried, yielding 4.8 parts (48.5%) of - ' : N-(2- (4-[ [1-[ (4-f1uorophenyl methyl] -1i-benzinidazol-2-y1 amino} ~~ } 20 piperidinyl]ethyl]-2-methyl-1H-inidazo (4, 5-blpyridin=5-anine; mp. 202.0°C (compound 146).
Example 58
A mixture of 6.5 parts of ethyl j-bromo-4-oxo-1-piperidine- carboxylate, 8.6 parts of N-(2-[4-[(1-[(4-fluorophenyl)methyl]= 1H-benzimidazol-2-yl]-amino) -1-piperidinyl]ethyl] thiourea and 80 parts of absolute ethanol was stirred and refluxed overnight. The reaction mixture was evaporated and water was added to the residue.
The free base was liberated with a sodium hydroxide solution and . extracted with 4-methyl-2-pentanone. The extract was dried, filtered and evaporated. The oily residue was converted into the (E)-2-butene- dicate salt in 2-propanone and ethanol. The salt was filtered off ‘ and dried, yielding 6.66 parts of ethyl 2-{12-{4-[[1-[4-fluoro- shenyl)methyl]-1H-benzimidazol-2-yl] amino) -1-piperidinyl]ethyl}= amino] -4,5-dihydro-thiazolo[4,5-d)pyridine=6(7H) ~carboxylate (E)-2-butenediocate (1:2) monohydrate; mp. 183.4°C (compound 147}. . ,
] ete ys -72-
Example 59 ’ '
A mixture of 7 parts of 6-chloro-N®- (2-(4~[ (1- [(4-fluoro~ r phenyl)methyl])-1H-benzimidazol-2-yl]amino]-1-piperidinylj- Co
BE ethyl] -4,5-pyrimidinediamine, 2.1 parts of carbon disulfide and 90 ’ - parts of N,N-dimethylformamide was stirred overnight at 70°C. The ' reaction mixture was poured into water. The product was extracted ' with trichloromethane. The extract was dried, filtered and Cr B evaporated. The residue was crystallized from ethanol. The product was filtered off and dried in vacuo overnight at 120°C, yielding 2.3
Co 10 parts (29%) of 7-[{2-[4-[[1~-{{4-fluorophenyl)methyl] ~1H-benz- . imidazol-2-yl)amino]-l-piperidinyl]ethyl)amino]-thiazolo(5,4-d]- " pyrimidine-2-thiol monohydrochloride; mp. 226.5°C (compound 148).
Example 60
A mixture of 2 parts of 2-thiazolamine, 12.7 parts of 1-bromo-4- : 15 {4-[[1-[(4~fluorophenyl)methyl] -1H-benzimidazol-2-yl]amino]-1-piperidi- " nyl]-2-butancne, 6.4 parts of sodium carbonate and 135 parts of ‘ methylbenzene was stirred and refluxed for 3 hours using a water oe separator. The whole was filtered and the filtrate was evaporated.
The residue was purified twice by column chromatography over silica : 20 gel using a mixture of trichloromethane and methanol, saturated with ammonia, (96:4 by volume) as eluent. The pure fractions were } collected and the eluent was evaporated. The residue was crystal- . lized from acetonitrile, yielding 0.5 parts (5.3%) of 1-((4-fluoro- phenyl)methyl] -N-[1-[2-(imidazo(2,1-b]thiazol-6-yl)ethyl])-4-piperi~ : 25 dinyl)}-1H-benzimidazol-2-amine; mp. 222.7°C (compound 149).
In a similar manner there were also prepared: 1- [(4-£luorophenyl)methyl]-N-[1-[2~(imidazo(1,2-a]pyridin-2-yl)ethyl}- 4-piperidinyl)-1H-benzimidazol-2-amine; mp. 208.0°C; (comp. 150): and ‘ 1- [{4-f1luorophenyl)methyl] -N-[1-[2-(imidazo(3,2-alpyrimidin-2-y1}- . 30 ethyl] -4-piperidinyl]-1H-benzimidazol-2-amine: mp. 263.8°C: (compound 151).
Example 61
A mixture of 4 parts of 1-[(4-fluorophenyl)methyl}-N-[1~ [(imidazo[l,2-a)pyrazin-2-yl)methyl]-4-piperidinyl]-1H~ benzimjdazol-2-amine, 50 parts of acetic acid and 80 parts of
Le be 5 -73~- methanol was hydrogenated at normal pressure and at 20°C with 2 parts of platinum-on-charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol, saturated with ammonia, (96:4 by volume) a® eluent. The pure fractions were collected and the eluent was evaporated. The residue was converted into the hydrochloride salt in ethanol. The salt was filtered off and dried, yielding 1.5 parts (32%) of 1-{(4-fluorophenyl)methyl]-N-[1- ((5,6,7,8-tetrahydroimidazo(l,2-a]pyrazin-2-yl)methyl]-4-piperidinyl] 1H-benzimidazol~2-amine trihydrochloride; mp. 279.7°C (compound 152).
The useful antihistaminic properties of the compounds of formula (1) are demonstrated in the following test procedure. 1S
Protection of rats from compound 48/80-induced lethality.
Compound 48/80, a mixture of oligomers obtained by condensation of 4-methoxy-N-methylbenzeneethanamine and formaldehyde has been i. described as a potent histamine releasing agent (Int. Arch. Allergy, 13, 336 (1958)). The protection from compound 48/80-induced lethal circulatory collapse appears to be a simple way of evaluating quantitatively the antihistaminic activity of test compounds. Male rats of an inbred Wistar strain, weighing 240-260 g were used in the experiment. After overnight starvation the rats were transferred to ‘ conditioned laboratories (temp. = 21 + 1°c, relative humidity = 65 + 5%).
The rats were treated subcutaneously or orally with a test compound or } with the solvent (NaCl solution, 0.9%). One hour after treatment there : 30 was injected intravenously compound 48/80, freshly dissolved in water, ’ at a dose of 0.5 mg/kg (0.2 ml/100 g of body weight). In control experimerits, wherein 250 solvent-treated animals were injected with the standard dose of compound 48/80, not more than 2.8% of the animals survived after 4 hours. Survival after 4 hours is therefore considered
Co 35 to be a safe criterion of a protective effect of drug administration.
lly -74-
The ED "values of the compounds of formula (I) are listed in the first column of table l. Said ED, "values are the values in mg/kg body weight at which the tested compounds protect 50% of the tested animals against compound 48/80-induced lethality. ’ 5 The compounds of formula (I) and the pharmaceutically acceptable oo acid addition salts thereof are also potent serotonin-antagonists. » to , The potency of the subject compounds as serotonin~antagonists is . clearly evidenced by the results obtained in the following tests wherein the antagonistic activity of the subject compounds on the : 10 effect of serotonin is examined. : Antagonistic activity on the effects of serotonin in the gastric : lesion test. —
A. Lesions induced by compound 48/80:
Compound 48/80 (a mixture of oligomers obtained by condensation of 4-methoxy-N-methylbenzeneethanamine and formaldehyde) is a potent releaser of vasoactive amines from endogenous stores such as, for example, histamine and serotonin. Rats injected with compound 48/80 exhibit consistent changes of blood flow in different vascular beds: cyanosis of the ears and the extremities are prominent within five minutes after injection of the compound; the rats die from shock within 30 minutes. The shock, followed by dead, can be avoided if the rats are pretreated with a classical H 1 antagonist.
However the stimulatory effects on gastric secretion are not suppressed so that rats treated with compound 48/80 and protected from shock by an H 1.antagonist may exhibit all signs of intensive ’ : gastric gland activity: gross autopsy shows distended stomachs with abnormal contents and rough bright red patches all over the mucosa, - corresponding to areas of disintegrated glands. A number of known serotonin-antagonists such as, for example, methysergide, cypro- heptadine: cinanserin, mianserin, pipamperone, spiperone, plzotifen and metergoline, prevent completely the cyanosis of ears and ’ 35 extremities as well as the lesions in the glandular area of the
Yio :
No
Dlr & . -75= stomach and the abnormal gastric distension.
B. Method:
Male rats of a Wistar inbred strain, weighing 220-250 g, were starved overnight, water being available ad libitum. The test compounds were administered orally as a solution or as a suspension in aqueous medium. A control rat«and a "blank" rat received the test compound. One hour later 5-[4~{diphenylmethyl)~-l-piperazinyl- methyl] -1-methyl-1H-benzimidazole-2-methanol was administered subcutaneously to all rats at the dose of 2.5 mg/kg. Two hours after the oral or subcutaneous administration of the test compound, the compound 48/80 (freshly solved in water at a concentration of 0.25 mg/ml) was injected intravenously into all rats (dose: 1 mg/kg) except ’ the "blank" rats.
Four hours after the intravenous injection of compound 48/80, the rats were decapitated and the stomachs were removed. Subsequently the stomachs were inspected for distension and contents (bleed, fluid, food) and thoroughly rinsed. The macroscopic lesions were scored from 0 to +++, 0 corresponding to complete absence of visible lesions and the highest score corresponding to reddish rough patches covering more than half the glandular area.
The second column of Table 1 shows for a number of compounds of formula (I) the doses (in mg/kg body weight) at which the distension of the stomach as well as the lesions in the glandular area of the stomach are completely absent in 50% of the test rats (EDg,-value).
The compounds listed in Table 1 are not given for the purpose of limiting the invention thereto but only to exemplify the useful pharmacological activities of all the compounds within the scope of formula (I). 3s ‘ k ele “. H, -76- oo
Table 1 to
Column 1 Column 2
Compound 48/80 gastric lesion
Comp . lethality test in test . 5 No. rats-EDgq in mg/kg EDgg in mg/kg body weight body weight cL 142 0.16 0.63 4 0.16 0.31 : 109 0.04 0.04 10 147 0.31 0.63
Poo 110 0.16 0.31 ; 111 0.02 0.08 ! 112 0.02 0.16 113 0.04 - 15 114 0.02 0.63 24 0.08 0.63 25 0.16 - 0.16 0.04 22 0.16 - 20 26 0.08 - 6 0.08 0.63 7 © 0.04 0.31 } 1 0.31 0.63 8 0.16 0.63 25 9 : 0.08 0.16 0.08 0.16 Po i I 115 0.02 0.16 3 27 0.08 - - : 11 0.08 0.04 . 10 12 0.16 0.31
B 28 0.04 0.16 0.16 - oo 31 0.04 0.02 a as
’ wo 4 -77-
Table 1 (cont'd)
Column 1 Column 2 : Compound 48/80 gastric lesion
Comp. lethality test in test ” body weight body weight 32 5.04 - 117 0.02 0.31 146 0.04 0.08 121 ‘ 0.02 0.02 122 0.02 0.63 . 119 0.04 0.63 108 0.04 0.16 34 0.08 0.16 35 0.02 - 13 0.02 0.08 14 0.02 - 36 0.16 - , : 15 0.16 0.31 37 0.16 - } 16 0.16 - 38 0.04 - 39 0.16 0.63 . 40 0.16 0.16 41 0.16 0.63 : 42 0.16 -
Co 43 0.16 - 44 0.16 - ’ - 45 0.08 - » 30 132 0.16 - , 150 0.08 0.63 17 0.31 0.63 18 0.08 0.16 129 0.08 0.31 48 0.08 -
: LG -78-
Table 1 (cont'd)
Column 1 Column 2
Compound 48/80 gastric lesion
Comp. lethality test in test
No. rats-EDg5g in mg/kg EDsg in mg/kg body wedght body weight 149 0.08 0.08 128 0.08 - 151 0.08 - 49 0.16 0.63 152 0.08 0.63 94 0.31 0.63 95 | 0.16 0.63 96 | 0.16 - 93 | 0.08 0.16 oo 144 : 0.08 : - 1, 97 | 0.08 | 0.04 143 | 0.31 | 0.63 | : 107 ! 0.16 - | ; 19 0.08 0.01 i 69 | 0.16 - 100 0.16 - C. 103 0.16 0.63 ' 70 0.31 0.63 102 0.08 - 68 0.08 - 104 0.16 0.31 74 0.04 0.16 20 0.04 0.63 75 0.01 - ‘ 3 oo 76 0.08 - i 77 0.16 0.31 i 21 0.04 0.63 oo 79 0.16 - 52 0.31 1.25 :
oo Pe 7 -79=
Table 1 (cont'd)
Column 1 Column 2
Compound 48/80 gastric lesion
Comp. lethality test in test s No. rats-EDgg in mg/kg EDgg in mg/kg i body weight body weight } 54 0.31 - 55 0.08 0.16 57 0.16 - ’ : } 10 58 0.04 0.63 . 59 . 0.08 0.31 61 0.04 0.31 62 0.04 0.63 63 0.08 0.63 80 0.16 0.63 64 0.08 0.31 66 0.16 0.63 .
In view of their antihistaminic and serotonin~antagonistic properties, the compounds of formula (I) and their acid-addition salts are very useful in the treatment of allergic diseases such as, for example, allergic rhinitis, allergic conjunctivities, chronic urticaria, allergic astma and the like.
In view of their useful pharmacological properties the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, a pharmaceutically effective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable ' carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharma- ceutical compositions are desirable in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as,,
' ete py, -80- : for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, ' to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid
Co 15 carriers, suspending agents and the like may be employed. Acid addition salts of (I), due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of adminis- tration and uniformity of dosage. Dosage unit form as used in the : specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired thera- peutic effect in association with the required pharmaceutical carrier.
Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic administration to animal and human subjects in accordance with the present invention.
These examples are given to illustrate and not to limit the scope of the present invention. :
. oll -81- "active ingredient” (n.1.) as used throughout these examples relates to 2 compound of formula (1), 2 possible gtereochemically jgomeric form OT pharmaceutically acceptable acid addition salt ] thereof .
Example 62 : ORAL DROPS 500 Grams of the A.1. was atssolved in 0.5 jiters of 2-hydroxy~ propanoic acid and 1.5 liters of the polyethylene glycol at 60-80°C.
After cooling to 40-40°C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added 2a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while gtirring there were added 2.5 liters of cocoa flavor } and polyethylene glycol q.s. to 2 volume of 50 Liters, providing an oral drop solution comprising 10 milligrams of the A.1. per milli- 1iter. The resulting golution was filled into guitable containers.
Example 63 : ORAL SOLUTION 9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified water. In 3 liters of this solution were dissolved first 10 grams of 2, 3-aihydroxybutanedict® acid and thereafter 20 grams of the A.1. The latter golution was combined with the remaining part of the former golution and 12 liters 1, 2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were aissolved jn 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence Were added. The latter solution was combined with the formeX, water was added 4.S- ro a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per reaspoonful (5 milliliters). The resulting golution was filled in suitable containers.
Example 64 : CAPSULES 20 Grams of the A.I., © grams godium jauryl sulfate, 56 grams ’ starch. 56 grams lactose: 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium gtearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.
: od cess -82-
Example 65 : FILM-COATED TABLETS
Preparation of tablet core
A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams . starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 milliliters of water. The wet powder mixture was sieved, . dried and sieved again. Then there was added 100 grams microcrystal- line cellulcse and 15 grans hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.
Coating . , To a solution of 10 grams methyl cellulose in 75 milliliters of " denaturated ethanol there was added a solution of 5 grams of ethyl oo
Ce cellulose in 150 milliliters of dichloromethane. Then there were added -
CT 4778 milliliters of aichloromethané and 2.5 milliliters 1 23 Lpgopane= his i triol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K~-1-2109) and the whole was homogenated.
The tablet cores were coated with the thus obtained mixture in a coating apparatus.
Example 66 : INJECTABLE SOLUTION 1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxy- benzoate were dissolved in about 0.5 liters of boiling water for injection. After cooling to about 50°C there were added while stirring 4 grams lactic acid, 0.05 propylene glycol and 4 grams of the A.I..
The solution was cooled to room temperature and supplemented with water for injection g.s. ad 1 liter volume, giving a solution of 4 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.
Example 67 : SUPPOSITORIES 3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxy- butanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams surfactant and triglycerides q.s. ad 300 grams were molten together.
° “ -83~
The latter mixture was mixed well with the former solution. The thus obtained mixture was poured onto moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 milligrams of the active ingredient.
The present invention is also related with a method of treating allergic diseases in warm-blooded animals suffering from said allergic diseases by administering an effective anti-allergic amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.
Suitable doses administered daily to subjects are varying from 0.1
Co to 100 mg, more preferably from 1 to 50 mg. is ' 14 : oe ra SET ELE Cos cet ECE . . } i tT yoo Uta
Claims (1)
1. A compound having the formula rR! N al Het-Y aN yn I NA Mm, H N RE a pharmaceutically acceptable acid addition salt or o sterecchemicallv isomeric form thereof, wherein: Al=A2-A3=A4 is a bivalent radical having the formula -CH=CH-CH=CH- (a), -N=CH-CH=CH- (b), or -CH=CH-CH=N- (e), wherein one hydrogen atom in said radical (a) may be replaced by lower alkyloxy or hydroxy; , Rlis phenyl or lower alkyl substituted with one Ar! radical: Ar! is unsubstituted phenyl, phenyl substituted with halo or lower alkyl; thienyl; furanyl; lower alkyl substituted furanyl; pyridiny] or thiazolyl ; All is lower alkanedivl; Y is O, S, NH or a direct bond; Het is a member of the group consisting of rR Rr!0 AX N._-R’ YO Nr Nr Bi _lL— @-1), (i-2) : SNR N— ’ N— (i-3), x! x! x! Rr? NR S_ R'S NR" GY XC as, ope || — G6 FY XT Gy, N——RY N AN
: . £ Gz 77 ,© 0 FF ’- R1® 0 : N x! ~ BS I ¥ (-8) and T (-9); wherein each X! is independently O or S; R7, R8, R10, R17 and R19 are each independently hydrogen, lower alkyl, ; (halophenyl)lower alkyl, hydroxylower alkyl or lower alkyloxycarbonyl; RY, R11, R14, R15, R16 and R18 are each independently hydrogen, lower alkyl, hydroxy, mercapto, lower alkyloxy, lower alkylthio, halo and (lower alkyloxycarbonyl)- j lower alkyl; : B! is -CH=CH-CH=CH-, -S-CH=CH- or -N=CH-NH-; B3 is -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH2-NH-(CH3)- or -S-CH=CH-; B4 is -CHy-NH-(CHp)z-, -N=CH-CH=CH- or -N=CH-N=CH-; BS is -N=CH-CH=CH-, -CH=N-CH=CH- or -CH=N-CH=N-; BS is -CH=CH-CH=CH- or -CH=N-CH=N-; > to wherein one or two hydrogen atoms in said radicals B1, B3, B4, BS or BS or in the benzene part of the radicals of formula (i-2), (i-3) or (i-9) may be replaced by lower alkyl, lower alkylthio, lower alkyloxy or halo where said hydrogen atom is bonded on a carbon atom, or by lower alkyl, lower alkyloxycarbonyl, (halophenyl)lower alkyl, where ' said hydrogen is bonded on a nitrogen atom, . R7,R8 R14 R15 R16 R17 or R18 being absent where the radical of formula (i-1), respectively (i-5), (i-6) and (i-7) is connected through the atom bearing R7, R8, R14, R15, R16 R17 or R810 Y, provided that : i) Y is a direct bond when Het is connected through a nitrogen atom to Y; : ; 25 ii) when Al=A2-A3=A4is a radical of formula (a) or (b) and Y is a direct bond then Het is other than a 2,3-dihydro-2-oxo- 1H-benzimidazol-1-yl or a 2,3-dihydro-3-oxo- ; benzoxazin-4-yl radical.
FRANS JANSSENS JOSEPH TORREMANS JOZEF HENS THEOPHILUS VAN OFFENWERT Inventors
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PH38315A PH26643A (en) | 1983-11-30 | 1989-03-10 | Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55674283A | 1983-11-30 | 1983-11-30 | |
US06/660,608 US4695569A (en) | 1983-11-30 | 1984-10-12 | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines |
PH31479A PH23692A (en) | 1983-11-30 | 1984-11-23 | Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)4-piperidinamines |
PH38315A PH26643A (en) | 1983-11-30 | 1989-03-10 | Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26643A true PH26643A (en) | 1992-09-04 |
Family
ID=27353985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH38315A PH26643A (en) | 1983-11-30 | 1989-03-10 | Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH26643A (en) |
-
1989
- 1989-03-10 PH PH38315A patent/PH26643A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0144101B1 (en) | Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines | |
EP0151826B1 (en) | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | |
US4695575A (en) | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines | |
EP0151824B1 (en) | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives | |
EP0206415B1 (en) | (4-piperidinylmethyl and -hetero)purines | |
EP0099139B1 (en) | Novel n-(bicyclic heterocyclyl)-4-piperidinamines | |
US4946843A (en) | 2-(heterocyclylalkyl)imidazopyridines | |
KR100206723B1 (en) | Novel substituted thiazolyl and substituted pyridinyl derivatives | |
EP0297661B1 (en) | [(Bicyclic heterocyclyl)methyl and -hetero] substituted hexahydro-1H-azepines and pyrrolidines | |
US4695569A (en) | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines | |
IE900068L (en) | 2-aminopyrimidinone derivatives | |
US4839374A (en) | 4-((Bicyclic heterocyclyl)-methyl and -hetero)-piperidines | |
US4943580A (en) | Anti-histaminic benzimidazole, imidazopyridine and purine derivatives | |
US5126339A (en) | Anti-allergic bicyclic heterocyclyl-containing N-(bicyclic heterocyclyl)-4-piperidinamines | |
US4888426A (en) | 1-(5-methyl-furan-2-ylmethyl)-N-(4-piperidinyl)imidazo [4,5-6]pyridine-2-amine | |
US5025014A (en) | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines as pharmaceuticals | |
PH26643A (en) | Bicyclic heterocyclic containing N-(bicyclic hetero-cyclyl)-4-piperidinamines | |
US5071846A (en) | Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines | |
CA1330081C (en) | Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines | |
KR880000489B1 (en) | Method for preparing N- (bicycle heterocyclyl) -4-piperidine amine | |
IE57722B1 (en) | N-(bicyclic heterocyclyl)-4-piperidinamines |